NZ623147B2 - Genetically modified t cell receptor mice - Google Patents
Genetically modified t cell receptor mice Download PDFInfo
- Publication number
- NZ623147B2 NZ623147B2 NZ623147A NZ62314712A NZ623147B2 NZ 623147 B2 NZ623147 B2 NZ 623147B2 NZ 623147 A NZ623147 A NZ 623147A NZ 62314712 A NZ62314712 A NZ 62314712A NZ 623147 B2 NZ623147 B2 NZ 623147B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- human
- tcr
- segments
- animal
- locus
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title claims abstract description 319
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 302
- 241000699670 Mus sp. Species 0.000 title description 74
- 241000282414 Homo sapiens Species 0.000 claims abstract description 972
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 298
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 195
- 210000004027 cell Anatomy 0.000 claims description 115
- 239000000427 antigen Substances 0.000 claims description 96
- 108091007433 antigens Proteins 0.000 claims description 95
- 102000036639 antigens Human genes 0.000 claims description 95
- 241000283984 Rodentia Species 0.000 claims description 83
- 241001465754 Metazoa Species 0.000 claims description 76
- 150000007523 nucleic acids Chemical group 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 55
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 54
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 26
- 238000012217 deletion Methods 0.000 claims description 19
- 230000037430 deletion Effects 0.000 claims description 19
- 230000011712 cell development Effects 0.000 claims description 17
- 239000012636 effector Substances 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 230000003393 splenic effect Effects 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 11
- 230000002992 thymic effect Effects 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 9
- 210000004988 splenocyte Anatomy 0.000 claims description 9
- 238000010367 cloning Methods 0.000 claims description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 271
- BSDCIRGNJKZPFV-GWOFURMSSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(2,5,6-trichlorobenzimidazol-1-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1Cl BSDCIRGNJKZPFV-GWOFURMSSA-N 0.000 description 152
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 description 147
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 description 147
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 description 146
- 108020004414 DNA Proteins 0.000 description 63
- 241000700159 Rattus Species 0.000 description 53
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 46
- 230000008685 targeting Effects 0.000 description 45
- 239000012634 fragment Substances 0.000 description 43
- 239000013598 vector Substances 0.000 description 41
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 238000003780 insertion Methods 0.000 description 24
- 230000037431 insertion Effects 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 21
- 238000011144 upstream manufacturing Methods 0.000 description 21
- 210000001541 thymus gland Anatomy 0.000 description 18
- 150000001413 amino acids Chemical group 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 238000000684 flow cytometry Methods 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 239000003623 enhancer Substances 0.000 description 14
- 238000002744 homologous recombination Methods 0.000 description 14
- 230000006801 homologous recombination Effects 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 108700028369 Alleles Proteins 0.000 description 13
- 102100032912 CD44 antigen Human genes 0.000 description 13
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 13
- 108010027252 Trypsinogen Proteins 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 12
- 230000009258 tissue cross reactivity Effects 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 230000000750 progressive effect Effects 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 210000001161 mammalian embryo Anatomy 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 230000008707 rearrangement Effects 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 9
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 description 9
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 description 9
- 102100033467 L-selectin Human genes 0.000 description 9
- 102100029454 T cell receptor alpha chain MC.7.G5 Human genes 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000006798 recombination Effects 0.000 description 9
- 238000005215 recombination Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 230000024245 cell differentiation Effects 0.000 description 8
- 210000005260 human cell Anatomy 0.000 description 8
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 210000003162 effector t lymphocyte Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- 101000794418 Homo sapiens T cell receptor alpha variable 41 Proteins 0.000 description 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 4
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 102100030198 T cell receptor alpha variable 41 Human genes 0.000 description 4
- 241000703392 Tribec virus Species 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 210000005210 lymphoid organ Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 108010051219 Cre recombinase Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 210000003751 DN2 alpha-beta immature T lymphocyte Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 101000658404 Homo sapiens T cell receptor beta variable 29-1 Proteins 0.000 description 3
- -1 Kit Proteins 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000699729 Muridae Species 0.000 description 3
- 102100034879 T cell receptor beta variable 29-1 Human genes 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000005220 cytoplasmic tail Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101150097493 D gene Proteins 0.000 description 2
- 210000001086 DN3 alpha-beta immature T lymphocyte Anatomy 0.000 description 2
- 210000001570 DN4 alpha-beta immature T lymphocyte Anatomy 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010046276 FLP recombinase Proteins 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 2
- 101000772137 Homo sapiens T cell receptor alpha variable 1-1 Proteins 0.000 description 2
- 101000658378 Homo sapiens T cell receptor alpha variable 13-2 Proteins 0.000 description 2
- 101000772107 Homo sapiens T cell receptor alpha variable 22 Proteins 0.000 description 2
- 101000794422 Homo sapiens T cell receptor alpha variable 35 Proteins 0.000 description 2
- 101000794370 Homo sapiens T cell receptor alpha variable 6 Proteins 0.000 description 2
- 101000606220 Homo sapiens T cell receptor beta variable 6-5 Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 241000398750 Muroidea Species 0.000 description 2
- 101100512543 Mus musculus Mcoln3 gene Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 241000121210 Sigmodontinae Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 102100029309 T cell receptor alpha variable 1-1 Human genes 0.000 description 2
- 102100034848 T cell receptor alpha variable 13-2 Human genes 0.000 description 2
- 102100029482 T cell receptor alpha variable 22 Human genes 0.000 description 2
- 102100030191 T cell receptor alpha variable 35 Human genes 0.000 description 2
- 102100030179 T cell receptor alpha variable 6 Human genes 0.000 description 2
- 102100039786 T cell receptor beta variable 6-5 Human genes 0.000 description 2
- 102000018690 Trypsinogen Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 102000025171 antigen binding proteins Human genes 0.000 description 2
- 108091000831 antigen binding proteins Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 102000050826 human ACKR2 Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 238000011714 129 mouse Methods 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 101150070234 31 gene Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 241000699725 Acomys Species 0.000 description 1
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 1
- 244000202285 Acrocomia mexicana Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101100460134 Caenorhabditis elegans ned-8 gene Proteins 0.000 description 1
- 241000398949 Calomyscidae Species 0.000 description 1
- 241000700193 Calomyscus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241001095404 Dipodoidea Species 0.000 description 1
- 208000025967 Dissociative Identity disease Diseases 0.000 description 1
- 101150018272 FYN gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001416537 Gliridae Species 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 101000658395 Homo sapiens Probable non-functional T cell receptor beta variable 17 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000794423 Homo sapiens T cell receptor alpha variable 34 Proteins 0.000 description 1
- 101000794424 Homo sapiens T cell receptor alpha variable 39 Proteins 0.000 description 1
- 101000794371 Homo sapiens T cell receptor alpha variable 5 Proteins 0.000 description 1
- 101000658393 Homo sapiens T cell receptor beta variable 18 Proteins 0.000 description 1
- 101000658408 Homo sapiens T cell receptor beta variable 30 Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101150028321 Lck gene Proteins 0.000 description 1
- 241001046461 Lophiomys imhausi Species 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000875057 Mus musculus Cannabinoid receptor 1 Proteins 0.000 description 1
- 101000875073 Mus musculus Cannabinoid receptor 2 Proteins 0.000 description 1
- 101001129925 Mus musculus Leptin receptor Proteins 0.000 description 1
- 241000699669 Mus saxicola Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 241000398990 Nesomyidae Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001338313 Platacanthomyidae Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100034883 Probable non-functional T cell receptor beta variable 17 Human genes 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000398956 Spalacidae Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 description 1
- 102100030190 T cell receptor alpha variable 34 Human genes 0.000 description 1
- 102100030189 T cell receptor alpha variable 39 Human genes 0.000 description 1
- 102100030178 T cell receptor alpha variable 5 Human genes 0.000 description 1
- 102100034882 T cell receptor beta variable 18 Human genes 0.000 description 1
- 102100034890 T cell receptor beta variable 30 Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000013564 activation of immune response Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003515 double negative t cell Anatomy 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000049265 human CDR1 Human genes 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003571 opsonizing effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Abstract
Disclosed is a genetically modified non-human animal, comprising in its genome: -an unrearranged T cell receptor (TCR) ? variable gene locus comprising at least one human V? segment and at least one human J? segment, wherein the TCR? variable gene locus is operably linked to a non-human TCR? constant gene sequence, wherein the unrearranged TCR? variable gene locus replaces an endogenous non-human TCR? variable gene locus, and/or -an unrearranged TCR? variable gene locus comprising at least one human V? segment, at least one human D? segment, and at least one human J? segment, wherein the unrearranged TCR? variable gene locus is operably linked to a non-human TCR? constant gene sequence, wherein the unrearranged TCR? variable gene locus replaces an endogenous non-human TCR? variable gene locus. nt gene sequence, wherein the unrearranged TCR? variable gene locus replaces an endogenous non-human TCR? variable gene locus, and/or -an unrearranged TCR? variable gene locus comprising at least one human V? segment, at least one human D? segment, and at least one human J? segment, wherein the unrearranged TCR? variable gene locus is operably linked to a non-human TCR? constant gene sequence, wherein the unrearranged TCR? variable gene locus replaces an endogenous non-human TCR? variable gene locus.
Description
CALLY MODIFIED T CELL RECEPTOR MICE
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of priority to US. Provisional Application No.
61/552,582, filed October 28, 2011; US. Provisional Application No. 61/621,198, filed April
6, 2012; and US. Provisional Application No. 61/700,908, filed September 14, 2012, all of
which are incorporated by reference herein in their entirety.
FIELD OF THE INVENTION
Present invention relates to a genetically ed man animal,
e.g., a
rodent (e.g., a mouse or a rat), that comprises in its genome human or humanized T Cell
Receptor (TCR) variable gene loci (e.g., TCR): and TCRfi le gene loci and/or TCR)
and TCRy variable gene loci), and expresses human or humanized TCR polypeptides (e.g.,
TCRoc and TCRS polypeptides and/or TCR?) and TCRy polypeptides) from the human or
humanized TCR variable gene loci. A non-human animal with human or humanized TCR
variable gene loci of the invention comprises unrearranged human TCR variable region
gene
segments (e.g., V, D, and/or J segments) at endogenous non-human TCR gene loci. The
invention also relates to embryos, tissues, and cells (e.g., T cells) that comprise human or
zed TCR variable gene loci and express human or humanized TCR polypeptides.
Also provided are methods for making the genetically modified non—human animal
comprising human or humanized TCR le gene loci; and methods of using man
animals, embryos, tissues, and cells that se human or humanized TCR variable gene
loci and express human or humanized TCR polypeptides from those loci.
BACKGROUND OF THE INVENTION
in the adaptive immune response, foreign antigens are recognized by receptor
molecules on B lymphocytes (e.g., immunogiobulins) and T lymphocytes (e.g., T cell
receptors or TCRs). While pathogens in the blood and extracellular space are recognized
by antibodies in the course of humoral immune response, destruction of pathogens inside
cells is mediated in the course of cellular immune response by T cells.
T cells ize and attack antigens presented to them in the context of a Major
Histocompatibility Complex (MHC) on the cell surface. The antigen ition is mediated
by TCRs sed on the surface of the T cells. Two main ciasses of T ceiis serve this
function: cytotoxic T cells, which express a cell-surface protein CD8, and helper T cells,
which express a ceii—surface protein CD4. Cytotoxic T celis activate signaling cascades that
result in direct destruction of the cell presenting the n (in the context of MHC i), while
helper T cells differentiate into several classes, and their activation (primed by recognition of
antigen presented in the context of MHC ii) resuits in macrophage-mediated pathogen
destruction and stimulation of antibody production by B cells.
Because of their antigen specificity, antibodies are presently widely studied for
their therapeutic potential against numerous human disorders. To te antibodies
capable of neutralizing human targets, whiie simultaneously avoiding activation of immune
responses against such antibodies, scientists have concentrated their s on producing
human or humanized immunogiobulins. One way of producing humanized antibodies in vivo
is by using VELOCIMMUNE® mouse, a humanized mouse comprising (1) ranged
human immunogiobuiin V, D, and J segment oire operably linked to each other and a
mouse constant region at the endogenous mouse immunogiobuiin heavy chain locus and (2)
ranged human VK and JK segment repertoire operably linked to each other and a
mouse constant K region at the endogenous mouse giobulin K light chain locus. As
such, VELOCIMMUNE® mice provide a rich source of highly diverse rearranged antibody
variable domains for use in engineering human antibodies.
Similar to an antibody, a T cell receptor comprises a variable region, d by
unrearranged loci (a and [5 loci, or a and y loci) sing V(D)J variable region segments,
and this variable region confers upon the T cell its antigen binding specificity. Also r to
an antibody, the TCR specificity for its antigen can be utilized for development of novel
therapeutics. Thus, there is a need in the art for man animals (e.g., rodents, e.g., rats
or mice) that comprise unrearranged human T cell variable region gene segments capable
of rearranging to form genes that encode human T cell receptor variable domains, ing
domains that are cognate with one another, and including domains that specifically bind an
antigen of interest. There is also a need for non-human animals that comprise T cell le
region loci that comprise conservative humanizations, including non-human animals that
comprise ranged human gene segments that can nge to form T cell receptor
variable region genes that are linked to non-human (endogenous) T cell receptor constant
gene sequences. There remains a need for non-human animals that are capable of
generating a diverse repertoire of human T cell receptor variable sequences. There is a
need for non-human animals that are capable of rearranging most or all functional T cell
receptor variable region segments, in response to an antigen of interest, to form T cell
receptor polypeptides that comprise fully human variable domains.
SUMMARY OF THE ION
Non-human animals, e.g., rodents, comprising non-human cells that express
humanized les that function in the cellular immune response are provided.
Nonhuman animals that comprise unrearranged TCR variable gene loci are also provided. In
vivo and in vitro systems are provided that comprise humanized rodent cells, wherein the
rodent cells express one or more humanized immune system molecules. ranged
humanized TCR rodent loci that encode humanized TCR proteins are also provided.
In one aspect, provided herein is a genetically modified non-human animal
(e.g., a rodent, e.g., a mouse or a rat) that comprises in its genome (a) an unrearranged
TCRα variable gene locus comprising at least one human Vα segment and at least one
human Jα segment, operably linked to a non-human (e.g., a rodent, e.g., a mouse or a rat)
TCRα constant gene sequence, and/or (b) an unrearranged TCRβ variable gene locus
comprising at least one human Vβ segment, at least one human Dβ segment, and at least
one human Jβ segment, operably linked to a non-human (e.g., a rodent, e.g., a mouse or a
rat) TCRβ constant gene sequence.
[0008a] In another aspect, provided herein is a cally modified non-human
animal, comprising in its genome:
an unrearranged T cell receptor (TCR) variable gene locus comprising at least one
human V t and at least one human J segment, wherein the TCR variable gene
locus is operably linked to a man TCR constant gene sequence, wherein the
unrearranged TCR le gene locus replaces an endogenous man TCR
variable gene locus, and/or
an unrearranged TCR variable gene locus comprising at least one human V
segment, at least one human D segment, and at least one human J segment, wherein the
unrearranged TCR variable gene locus is operably linked to a non-human TCR constant
gene sequence, wherein the unrearranged TCR variable gene locus replaces an
endogenous non-human TCR variable gene locus.
In one embodiment, the unrearranged TCRα variable gene locus replaces
endogenous non-human (e.g., rodent) TCRα variable gene locus at an endogenous TCRα
variable gene locus. In one ment, the unrearranged TCRβ le gene locus
replaces the endogenous non-human (e.g., rodent) TCRβ variable gene locus at an
endogenous TCRβ variable gene locus. In one embodiment, the nous non-human
(e.g., rodent) Vα and Jα segments are incapable of rearranging to form a rearranged Vα/Jα
sequence. In one embodiment, the endogenous non-human (e.g., rodent) Vβ, Dβ, and Jβ
segments are incapable of rearranging to form a rearranged Jβ ce. In one
embodiment, the non-human animal comprises a deletion such that the genome of the
animal does not comprise a functional Vα and functional Jα segment. In one embodiment,
the non—human animal comprises a deletion such that the genome of the animal does not
comprise a functional endogenous VB, a functional endogenous DB, and a functional
endogenous Jfi t. in one embodiment, the animal comprises a deletion of all
functional endogenous Va and Ja segments. in one embodiment, the rodent comprises a
deletion of all functional endogenous VB, D6, and J0 segments. in some embodiments, the
human V0: and Joe segments rearrange to form a nged VOL/Jet sequence. in some
ments, the human VB, DB, and J13 segments rearrange to form a nged
VB/DB/Jfi sequence. Thus, in various embodiments, the non—human animal (e.g., rodent)
ses a T cell receptor comprising a human le region and a non—human (e.g.,
rodent) constant region on a surface of a T cell.
ln some aspects, T cells of the non—human animal undergo T cell development in
the thymus to produce CD4 and CD8 single positive T cells. in some aspects, the non—
human animal comprises a normai ratio of splenic CD3+ T cells to total splenocytes. In
various embodiments, the non—human animal generates a population of central and effector
memory T cells in the periphery.
In one embodiment, the unrearranged TCRa le gene locus in the non-
human animal described herein ses 61 human Ja segments and 8 human Von
segments. in another embodiment, the unrearranged TCRoc variable gene locus in the non—
human animal comprises a complete repertoire of human Jo: segments and a complete
repertoire of human Va segments.
In one embodiment, the unrearranged TCRB variable gene locus in the non-
human animal described herein comprises 14 human JB segments, 2 human DB segments,
and 14 human st segments. in another embodiment, the unrearranged TCRfi le
gene locus in the non-human animal ses a complete repertoire of human JB
segments, a complete repertoire of human DB ts, and a complete repertoire of
human Vfi segments.
in an additional embodiment, the non-human animal described herein (e.g., a
rodent) further comprises nucleotide sequences of human TCRo variable segments at a
humanized TCRoc locus. in one embodiment, the non-human animal (e.g., rodent) r
comprises at least one human V5, D6, and J6 segments, e.g., a complete repertoire of
human V6, D5, and J6 segments at the humanized TCRor locus.
in one embodiment, the non-human animal retains an endogenous non-human
TCRor and/or TCRfi locus, wherein the locus is a non—functional locus.
ln one embodiment, the non—human animal is a rodent. In one embodiment, the
rodent is selected from a mouse and a rat. In one embodiment, the rodent is a mouse.
In one aspect, the invention provides a genetically modified mouse comprising in
its genome (a) an unrearranged TCRa variable gene locus comprising a repertoire of human
Joc segments and a repertoire of human Va segments, operably linked to a non—human (e.g.,
mouse or rat) TCRoc constant gene ce, and/or (b) an ranged TCRfi variable
gene locus comprising a repertoire of human JB segments, a repertoire of human DB
segments, and a repertoire of human V13 segments, operably linked to a non-human (e.g., a
mouse or rat) TCRB constant gene sequence. In one ment, the mouse comprises a
complete repertoire of human Va segments. In one embodiment, the mouse comprises a
complete repertoire of human Vfi segments. ln one ment, the mouse comprises a
te repertoire of human Va segments and human Jon segments. In one embodiment,
the mouse comprises a complete repertoire of human Voc segments and human VB
segments. In one embodiment, the mouse comprises a complete repertoire of human Voc,
human Jon, human V6, human DB, and human JB segments.
In one embodiment, the mouse comprises at least one endogenous mouse Va
and at least one endogenous mouse Jo: segment, wherein the endogenous segments are
incapable of nging to form a rearranged t sequence, and also comprises at least
one endogenous mouse Vfi, at least one endogenous mouse Dfs, and at least one
nous mouse J13 segment, wherein the endogenous segments are incapable of
rearranging to form a rearranged VB/DB/Jfi sequence.
In one embodiment, the unrearranged TCRa variable gene locus that comprises
human TCRa variable region segments replaces mouse TCRoc variable genes at the
endogenous mouse TCRoc variable locus, and the unrearranged TCRB variable gene locus
that ses human TCRB variable region ts replaces mouse TCRfi variable
genes at the endogenous mouse TCRB variable locus.
In one embodiment, the human Va and Ja ts rearrange to form a
rearranged human Von/Jon sequence, and the human VB, D0, and JB ts rearrange to
form a rearranged human Vp/DB/Jfi sequence. in one embodiment, the rearranged human
Von/Jo: sequence is operably linked to a mouse TCRoc constant region sequence. in one
embodiment, the rearranged human Vfi/DB/JB sequence is operably linked to a mouse
TCR[3 constant region ce. Thus, in various embodiments, the mouse expresses a T
cell receptor on the surface of a T cell, n the T cell or comprises a human
variable region and a mouse constant region.
In one embodiment, the mouse further comprises a repertoire of human TCRé
variable region segments (e.g., human V6, J6, and D6 segments) at a humanized TCRa
locus. In one embodiment, the repertoire of human TCR?) variable region segments is a
complete human TCRé variable region segment repertoire. In one embodiment, the human
TCR6 variable region segments are at the nous TCRoc locus. In one embodiment,
the human TCRo variable region segments replace endogenous mouse TCRé variable
region segments.
In one embodiment, the genetically modified mouse ses a T cell receptor
comprising a human variable region and a mouse constant region on a surface of a T cell.
In one aspect, the T cells of the mouse undergo thymic T cell development to produce CD4
and CD8 single ve T cells. In one aspect, the mouse comprises a normal ratio of
splenic CD3+ T cells to total splenocytes; in one aspect, the mouse generates a population
of central and effector memory T cells to an antigen of interest.
Also provided are methods for making genetically modified non-human animals
(e.g., rodents, e.g., mice or rats) described herein.
In one aspect, a method for making a humanized rodent (e.g., a mouse or rat) is
provided, comprising replacing rodent TCRor and TCRiS le region segments, but not
rodent constant genes, with human unrearranged TCRor and TCRB variable region
segments, at endogenous rodent TCR loci. In one embodiment, the method comprises
replacing rodent TCRa variable region ts (Va and/or Jor) with human TCRoc variable
region segments (Von and/or Jor), wherein the TCRor variable region segments are operably
linked to a non—human TCR constant region gene to form a zed TCRoc locus; and
replacing rodent TCR|3 variable region ts (VB and/or DB and/or JB) with human
TCRfi variable region segments (VB and/or D6 and/or J6), wherein the TCRB variable region
segments are operably linked to a non-human TCR constant region gene to form a
humanized TCRiS locus. In one embodiment, the humanized rodent is a mouse and the
germline of the mouse comprises the human TCRoc variable region segments operably
linked to an endogenous mouse TCRoc constant ce at an endogenous TCRor locus;
and the germline of the mouse ses the human TCRB le region segments
operably linked to an endogenous mouse TCRB constant sequence at an endogenous
TCRB locus.
in one embodiment, provided herein is a method for making a genetically
modified non—human animal (e.g., rodent, e.g., mouse or rat) that expresses a T cell receptor
comprising a human or humanized le region and a non-human (e.g., rodent) constant
region on a surface of a T cell comprising: replacing in a first non-human animal an
endogenous non-human TCRoc variable gene locus with an unrearranged humanized TCRa
variable gene locus sing at least one human Va segment and at least one human Ja
segment, wherein the zed TCRoc le gene locus is operably linked to
endogenous non-human TCRoc constant region; replacing in a second man animal an
endogenous non-human TCRB variable gene locus with an unrearranged humanized TCRfi
variable gene locus comprising at least one human V6 segment, at least one human DE»
t, and at least one human JB t, wherein the humanized TCRfi variable gene
locus is operably linked to endogenous TCRB constant ; and breeding the first and the
second man animal to obtain a non-human animal that expresses a T cell receptor
comprising a human or humanized variable region and a non—human constant .
in one embodiment of the method, the endogenous non—human (e.g., rodent) V0:
and Jon segments are incapable of rearranging to form a rearranged Von/Joe sequence and
the endogenous non-human (e.g., rodent) V6, DB, and J6 segments are incapable of
rearranging to form a rearranged Vfi/Dfi/JB sequence. in one embodiment of the method,
the human Va and Joe segments rearrange to form a rearranged Va/Ja sequence and the
human W5, DB, and J6 segments rearrange to form a rearranged Vp/Dfi/Jfi ce. In
one embodiment of the method, the unrearranged zed TCRoc variable gene locus
comprises 61 human Jor segments and 8 human Va segments, and the unrearranged
humanized TCRfi variable gene locus comprises 14 human VB segments, 2 human DB
segments, and 14 human Jfi segments. in another embodiment of the method, the
ranged humanized TCRa variable gene locus comprises a complete repertoire of
human Ja segments and a complete oire of human Va ts, and the
unrearranged humanized TCRB le gene locus comprises a complete repertoire of
human V5 segments, a complete repertoire of human DB segments, and a complete
repertoire of human Jfi segments.
in one aspect of the method, the T cells of the non-human animal (e.g., rodent)
undergo thymic T cell development to produce CD4 and CD8 single positive T cells. in one
aspect, the non—human animal (e.g., the rodent) comprises a normal ratio of splenic CD3+ T
cells to total splenocytes. In one aspect, the non—human animal (e.g., rodent) generates a
population of central and effector memory T cells to an antigen of interest.
In some embodiments, the replacement of the endogenous non-human TCRoc
variable gene locus described herein is made in a single ES cell, and the single ES cell is
introduced into a non-human (e.g., a rodent, e.g., a mouse or rat) embryo to make a
genetically modified non—human animal (i.e., the first non-human , e.g., the first
rodent); and the replacement of the endogenous non-human TCRfi variable gene locus
described herein is made in a single ES cell, and the single ES cell is introduced into a non-
human (e.g., a rodent, e.g., a mouse or rat) embryo to make a genetically modified non-
human animal (i.e., the second non-human animal, e.g., the second rodent). in one
embodiment, the first rodent and the second rodent are bred to form a progeny, wherein the
progeny comprises in its germline a humanized TCRa variable locus and a humanized
TCRfi variable locus.
in one embodiment of the method, the non-human animal is a rodent, e.g., a
mouse. Thus, the t invention also provides a method for making a genetically
modified mouse.
Also provided herein are cells, e.g., isolated T cells (e.g., cytotoxic T cells, helper
T cells, memory T cells, etc.), derived from the non-human s (e.g., rodents, e.g., mice
or rats) described herein. Tissues and embryos derived from the man animals
described herein are also provided.
In one aspect, a method for making a human TCR variable domain is provided,
comprising cally modifying a rodent as described herein to comprise a humanized
TCRa locus and/or a humanized TCRB locus, maintaining the rodent under conditions
sufficient to form a T cell, wherein the T cell expresses a human TCRa and/or a human
TCRB variable domain.
in one aspect, a method for making a nucleic acid sequence encoding a human
TCR variable domain that binds an epitope of interest is provided, comprising exposing a
non-human animal as described herein to an epitope of st, ining the non-human
animal under conditions ient for the animal to present the epitope of interest to a
humanized TCR of the animal, and identifying a nucleic acid of the animal that encodes a
human TCR variable domain ptide that binds the epitope of interest.
in one , use of a non-human animal as bed herein is provided for
making a humanized TCR receptor. in one aspect, use of a non-human animal as described
herein is provided for making a human TCR variable domain. in one aspect, use of a non—
human animal as described herein is provided for making a c acid sequence encoding
a human TCR le domain.
In one aspect, use of nucleic acid sequence encoding a human TCR variable
domain or fragment thereof to make an antigen-binding protein is provided. In one
embodiment, the antigen-binding protein comprises a TCR variable domain comprising a
human TCRa and/or human TCRL’» variable domain that binds an n of interest.
In one , use of a non-human as described herein is provided for making a
non—human cell that expresses on its surface a zed T cell receptor.
In one aspect, a humanized T cell receptor from a non-human animal as
described herein is provided.
In one , a nucleic acid sequence encoding a human TCR variable domain
or fragment thereof, made in a non-human animal as described herein, is provided.
Any of the embodiments and aspects described herein can be used in
conjunction with one another, unless otherwise indicated or apparent from the context.
Other embodiments will become nt to those skilled in the art from a review of the
ensuing detailed description. The following detailed description es exemplary
entations of various embodiments of the invention, which are not restrictive of the
invention as claimed. The accompanying figures constitute a part of this specification and,
together with the description, serve only to illustrate embodiments and not to limit the
invention.
BRIEF DESCRIPTION OF THE DRAWINGS
depicts ction in a mouse between a TCR molecule and an MHC
molecule: the left panel shows a mouse T cell (top) from a humanized TCR mouse
comprising a T cell receptor with human variable TCR domains and mouse constant TCR
domains, which recognizes an antigen (grey ball) presented through an MHC class I by an
antigen presenting cell (bottom); the right panel shows the same for an MHC class II. The
MHC I and MHC II complexes are shown together with their respective co—receptors, CD8
and CD4. Mouse regions are in black and human s are in white.
depicts (not to scale) the l organization of a mouse (top panel, first
locus) and human (top panel, second locus) TCRa locus. The bottom panel illustrates a
strategy for ing TCRoc variable region segments in a mouse (closed s) with
human TCRoc variable region segments (open symbols) at the endogenous mouse locus on
chromosome 14; a humanized TCRoc locus having human Va and Jo: segments is shown
with a mouse constant region and a mouse enhancer; in the embodiment shown, the TCRE)
locus is d in the course of humanization.
depicts (not to scale) a progressive strategy for humanization of the
mouse TCRoc locus, wherein TCRa variable region gene segments are sequentially added
upstream of an initial humanization of a deleted mouse locus (MAID1540). Mouse sequence
is indicated by closed symbols; human sequence is indicated by open symbols. MAID refers
to modified allele ID number. TRAV=TCR Voc segment, TRAJ=TCR Jet segment
(hTRAJ=human TRAJ), TRAC=TCR Cor domain, TCRD=TCR6.
is a detailed depiction (not to scale) of progressive humanization strategy
at the TCRd locus. depicts on of the mouse TCRd V and J segments; depicts strategy for insertion of 2V and 61J human segments into the deleted mouse
TCRa locus; depicts strategy for insertion of additional human V ts,
resulting in a total of 8V and SH human segments; s strategy for insertion of
additional human V segments, resulting in a total of 23V and GM human segments;
depicts strategy for insertion of additional human V ts resulting in 35V and (SH
human segments; depicts strategy for insertion of additional human segments
resulting in 48V and SH human segments; and depicts strategy for ion of
additional human segments ing in 54V and 61J human segments. MAID refers to
modified allele ID number.
depicts (not to scale) one embodiment of mouse TCRa locus
humanization gy, in which human TCR 6 sequences (TCRo Vs, TCRo Ds, TCRo Js,
TCR8 enh (enhancer), and TCRo constant (0)) are also placed at the humanized TCRor
locus. Mouse ce is indicated by closed symbols; human sequence is indicated by
open symbols. LTVEC refers to a large targeting ; hTRD=human TCRé.
depicts (not to scale) the general organization of a mouse (top panel, first
locus; on mouse some 6) and human (top panel, second locus; on human
chromosome 7) TCRB loci. The bottom panel illustrates a strategy for replacing TCRfi
variable region segments in the mouse (closed symbols) with human TCRE variable region
segments (open symbols) at the endogenous mouse locus on mouse chromosome 6. The
humanized TCRB locus having human Vfi, DB, and JB segments is shown with mouse
constant s and a mouse enhancer; in the embodiment shown, the zed locus
retains mouse trypsinogen genes (solid rectangles); and in the particular embodiment
shown, a single mouse V segment is retained upstream of the 5’ mouse trypsinogen genes.
depicts (not to scale) a progressive strategy for zation of the
mouse TCRB locus, wherein TCRfi variable region gene segments are sequentially added to
a deleted mouse TCRfi variable locus. Mouse sequence is ted by closed symbols;
human sequence is indicated by open symbols. MAID refers to modified allele ID number.
TRBV or TCRBV= TCRB V segment.
is a detailed depiction of progressive humanization strategy at the TCRB
locus. depicts the strategy for deletion of the mouse TCRB V segments; FIG. BB
depicts the strategy for insertion of 14V segments into the deleted TCRfS locus;
depicts the strategy for insertion of 2D and 14J segments into TCRB locus (i), followed by
deletion of the onP site (ii), resulting in 14V, 2D and 14J human ts; depicts
the strategy for inserting additional human V ts resulting in 40V, 2D and 14J human
segments; and depicts the strategy for insertion of additional human V ts
resulting in the 66V, 2D and 14J human segments; depicts replacement of the
mouse V segment downstream of a mouse enhancer, resulting in 67V, 2D and 14J human
segments. In this particular embodiment, one mouse V segment is retained 5’ of the mouse
trypsinogen genes.
depicts representative FACS analysis histograms for percent spleen cells
(where Y axis is number of cells, X axis is mean scence intensity, and the gate shows
frequency of CD3+ T cells within the single lymphocyte population) d with anti—CD3
antibody in a wild type (WT) mouse; a mouse homozygous for a deleted TCRoc locus (first
top panel; MAID 1540 of ; a mouse homozygous for a deleted TCRoc locus and
comprising 8 human Va and 61 human Joc segments (second top panel; MAID 1767 of or a zed TCRa mouse); a mouse homozygous for a deleted TCRB locus with the
exception of one upstream and one downstream mouse V6 segments (first bottom panel;
MAID 1545 of ; a mouse homozygous for a deleted TCRB locus with one upstream
and one downstream mouse V13 segments and comprising 14 human VB, 2 human D6, and
14 human JB segments (second bottom panel; MAID 1716 of or a humanized TCRfi
mouse); and a mouse homozygous for both TCRa and TCRB loci ons (with the
exception of said two mouse V13 segments) and comprising 8 human Va and 61 human Ja
ts at the endogenous TCRa locus as well as 14 human VB, 2 human D6, and 14
human J6 ts at the endogenous TCRB loci (MAID 1767/1716 or a zed
TCRa/B mouse).
is a representative FACS contour plot of mouse thymus cells from a WT,
homozygous zed TCch (1767 H0; hTCRoc); homozygous humanized TCRB (1716
H0; hTCsz’o); and gous humanized TCRoc/B mouse (1716 H0 1767 H0; hTCRoc/fi)
stained with anti—CD4 (Y axis) and anti—CD8 (X axis) antibodies (top panel), and anti—CD44
(Y axis) and anti-C025 (X axis) antibodies (bottom panel). The FACS plot in the top panel
allows to distinguish double negative (DN), double positive (DP), CD4 single positive (CD4
SP), and CD8 single positive (SP CD8) T cells. The FACS plot in the bottom panel allows to
distinguish various stages of double negative T cells during T cell development (DN1, DN2,
DN3, and DN4). 1716 and 1767 referto MAID numbers as identified in FIGs. 3 and 7.
trates either frequency (top panel) or absolute number (bottom
panel) of DN, DP, CD4 SP, and CD SP T cells in the thymus of either WT, hTCRa (1767
H0); hTCRB (1716 H0); or hTCRoc/ffi (1716 H0 1767 H0) mice (n=4).
is a representative FACS analysis of spleen cells of a WT, hTCRa (1767
H0); hTCRfi (1716 H0); or hTCRoc/B (1716 H0 1767 H0) mouse: left panel represents
is of singlet cells based anti—CD19 antibody (Y axis; stain for B lymphocytes) or anti-
CD3 dy (X axis; stain for T lymphocytes) staining; middle panel represents analysis of
CD3+ cells based on anti-CD4 (Y axis) or D8 (X axis) antibody staining; and right
panel represents analysis of either CD4+ or CD8+ cells based on anti—CD44 (Y axis) or anti-
CD62L (X axis) antibody staining, the stains allow to distinguish various types of T cells in
the periphery (naive T cells vs. l memory T cells (Tcm) vs. effector or effector memory
T cells (Teff/Tem)).
demonstrates the number of CD4+ (left panel) or CD8+ (right panel) T
cells per spleen (Y axes) of WT, hTCRa (1767 H0); hTCRfi (1716 H0); or hTCRoc/fi (1716
.H0 1767 H0) mice (n=4).
demonstrates the number of T na'ive, Tcm, and Teff/em cells per spleen
(Y axes) of CD4+ (top panel) or CD8+ (bottom panel) T cells of WT, hTCRa (1767 H0);
hTCRB (1716 H0); or hTCRon/[B (1716 H0 1767 H0) mice (n=4).
are tables izing expression (determined by FACS analysis using
variable segment-specific antibodies) of various human TCRB V segments in the splenic
CD8+ T cells (A) or CD4+ T cells (B) of WT, hTCRB (1716 H0) or hTCRa/B
(1716 H0 1767 H0) mice. Data presented as Mean:SD (n=4 mice per group)
depicts mRNA expression (Y axes) of various human TCRB V ts
present in WT, hTCRa (1767 H0); hTCRB (1716 H0); or hTCRa/B (1716 HO1767 HO)
mice in thymic or splenic T cells; A represents analysis of mRNA sion of
human TCRB variable segment (hTRBV) 18, 19, 20, and 24; and B ents
analysis of mRNA expression of hTRBV 25, 27, 28, and 29.
depicts representative FACS histograms of spleen cells (where Y axis is
number of cells, X axis is mean fluorescence intensity, and the gate shows frequency of
CD3+ T cells within the single lymphocyte population) stained with anti-CD3 antibody in a
WT mouse, a mouse homozygous for a deleted TCRor locus (TCRA AV), a mouse
homozygous for deleted TCRoc locus With 2 human V segments and 61 human J segments
(TCRA 2 hV; MAID 1626 of , a mouse homozygous for deleted TCRoc locus with 8
human V segments and 61 human J segments (TCRA 8 hV; MAID 1767 of , and a
mouse homozygous for deleted TCRoc locus with 23 human V segments and 61 human J
segments (TCRA 23 hV; MAID 1979 of .
, at left top panel, is a representative FACS analysis of CD3+ T cells of
the thymus obtained from either a WT or homozygous hTCRoc mouse with 23 human V
segments and 61 human J segments (1979 H0) stained with either anti-CD4 (Y axis) or anti—
CD8 (X axis) antibody; at left bottom panel, is a FACS analysis of DN T cells from either a
WT or 1979 mouse stained with either anti—CD44 (Y axis) or anti—CD25 (X axis); at right
panel are graphs of percent of ytes (Y axis) that are DN, DP, CD4 SP, or CD8 SP in
either WT or 1979 H0 mice (n=4).
, at left panel, is a representative FACS is of splenic lymphocytes
from a WT or 1979 H0 mouse d either with anti—CD19 or anti—CDB antibodies; at right
panel, are graphs of percent splenocytes (Y axis) obtained from WT and 1979 H0 mice
(n=4) that are CD3+.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
The present invention provides genetically modified non-human s, e.g.,
rodents, e.g., mice or rats, that express zed T cell receptors. The present invention
also relates to genetically modified non-human animals that comprise in their germline
unrearranged T cell receptor variable gene loci. Also provided are embryos, cells, and
tissues comprising the same; methods of making the same; as well as methods of using the
same. Unless defined othenNise, all terms and s used herein include the meanings
that the terms and s have attained in the art, unless the contrary is clearly ted or
clearly apparent from the context in which the term or phrase is used.
The term "conservative,” when used to describe a conservative amino acid
substitution, includes substitution of an amino acid e by another amino acid e
having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity).
vative amino acid substitutions may be achieved by modifying a tide sequence
so as to introduce a nucleotide change that will encode the conservative substitution. In
general, a conservative amino acid substitution will not substantially change the functional
properties of interest of a n, for e, the ability of a T cell to recognize a peptide
presented by an MHC molecule. Examples ofgroups of amino acids that have side chains
with similar chemical properties include aliphatic side chains such as glycine, alanine, valine,
leucine, and isoleucine; aliphatic-hydroxyl side chains such as serine and threonine; amide—
containing side chains such as asparagine and glutamine; aromatic side chains such as
phenylalanine, tyrosine, and tryptophan; basic side chains such as lysine, arginine, and
histidine; acidic side chains such as aspartic acid and glutamic acid; and, sulfur-containing
side chains such as cysteine and methionine. Conservative amino acids tution groups
include, for example, valine/leucine/isoleucine, phenylalanine/tyrosine, lysine/arginine,
alanine/valine, glutamate/aspartate, and asparagine/glutamine. In some embodiments, a
conservative amino acid substitution can be a tution of any native residue in a protein
with alanine, as used in, for e, alanine ng mutagenesis. In some
embodiments, a conservative substitution is made that has a positive value in the PAM250
log-likelihood matrix disclosed in Gonnet et al. ((1992) Exhaustive Matching of the Entire
Protein Sequence Database, Science 256:1443—45), hereby incorporated by reference. ln
some embodiments, the substitution is a moderately conservative tution wherein the
substitution has a nonnegative value in the PAM250 log-likelihood matrix.
Thus, encompassed by the invention is a genetically modified man animal
expressing humanized TCR oz and {3 polypeptides (and/or humanized TCRB and TCRy
polypeptides) comprising conservative amino acid substitutions in the amino acid sequence
described herein.
One skilled in the art would understand that in addition to the nucleic acid
residues encoding humanized TCR a and [3 polypeptides described herein, due to the
degeneracy of the genetic code, other nucleic acids may encode the ptides of the
invention. ore, in addition to a genetically modified non-human animal that comprises
in its genome nucleotide sequences encoding humanized TCR polypeptides described
herein, a non-human animal that comprises in its genome nucleotide sequences that differ
from those described herein due to the racy of the genetic code are also provided.
The term “identity” when used in connection with sequence includes identity as
determined by a number of different algorithms known in the art that can be used to
measure nucleotide and/or amino acid ce identity. In some embodiments described
herein, identities are ined using a ClustalW v. 1.83 (slow) alignment employing an
open gap penalty of 10.0, an extend gap penalty of 0.1, and using a Gonnet rity matrix
(MacVectorTM 10.0.2, MacVector Inc, 2008). The length of the ces compared with
respect to identity of sequences will depend upon the particular ces. In various
2012/062065
embodiments, identity is determined by comparing the sequence of a mature protein from its
inal to its C-terminal. In various embodiments, when comparing a chimeric
human/non-human sequence to a human sequence, the human portion of the chimeric
human/non-human sequence (but not the non-human portion) is used in making a
ison for the purpose of ascertaining a level of identity between a human sequence
and a human portion of a chimeric human/non—human sequence (e.g., comparing a human
main of a chimeric mouse protein to a human ectodomain of a human
protein).
The terms “homology” or “homologous” in reference to sequences, e.g.,
nucleotide or amino acid sequences, means two sequences which, upon optimal ent
and comparison, are identical in at least about 75% of nucleotides or amino acids, at least
about 80% of nucleotides or amino acids, at least about 90-95% nucleotides or amino acids,
e.g,, greater than 97% nucleotides or amino acids. One skilled in the art would understand
that, for optimal gene targeting, the targeting construct should contain arms homologous to
endogenous DNA sequences (i.e., “homology arms”); thus, homologous recombination can
occur between the ing construct and the targeted endogenous sequence.
The term "operably linked" refers to a juxtaposition wherein the components so
described are in a onship permitting them to function in their intended . As
such, a nucleic acid sequence ng a protein may be operably linked to regulatory
ces (e.g., promoter, er, silencer sequence, etc.) so as to retain proper
transcriptional regulation. in addition, various portions of the humanized protein of the
ion may be operably linked to retain proper folding, processing, targeting, sion,
and other functional properties of the protein in the cell. Unless stated othenrvise, various
domains of the humanized protein of the invention are operably linked to each other.
The term “replacement” in reference to gene replacement refers to placing
exogenous genetic material at an endogenous genetic locus, thereby replacing all or a
portion of the endogenous gene with an orthologous or homologous nucleic acid sequence.
in one instance, an endogenous non-human gene or fragment thereof is replaced with a
corresponding human gene or fragment thereof. A corresponding human gene or fragment
f is a human gene or fragment that is an ortholog of, a homolog of, or is substantially
identical or the same in ure and/or function, as the endogenous non—human gene or
nt thereof that is replaced. As demonstrated in the Examples below, nucleotide
sequences of endogenous non—human TCR 0L and 5 variable gene loci were replaced by
nucleotide sequences corresponding to human TCR a and [3 variable gene loci.
“Functional” as used herein, e.g., in reference to a functional protein, refers to a
protein that retains at least one biological activity normally ated with the native protein.
For example, in some embodiments of the invention, a replacement at an nous locus
(e.g., replacement at endogenous non—human TCRor, TCRB, TCRo and/or TCRy le
gene loci) results in a locus that fails to express a functional endogenous protein.
TCR locus or TCR gene locus (e.g., TCRoc locus or TCRB locus), as used herein,
refer to the genomic DNA comprising the TCR coding region, including the entire TCR
coding , including unrearranged V(D)J sequences, enhancer, sequence, constant
sequence(s), and any upstream or downstream (UTR, regulatory regions, etc), or
intervening DNA sequence (introns, etc). TCR variable locus or TCR variable gene locus
(e.g., TCRor le gene locus or TCRB variable gene locus), refers to genomic DNA
comprising the region that includes TCR variable region segments (V(D)J region) but
excludes TCR constant sequences and, in various embodiments, enhancer sequences.
Other sequences may be included in the TCR le gene locus for the purposes of
genetic manipulation (e.g., ion cassettes, restriction sites, etc), and these are
encompassed herein.
cally Modified TCR Animals
in s embodiments, the invention generally provides genetically modified
non—human animals wherein the non—human animals comprise in the genome unrearranged
humanized TCR variable gene loci.
T cells bind epitopes on small antigenic determinants on the surface of antigen-
presenting cells that are associated with a major histocompatibility complex (MHC; in mice)
or human leukocyte antigen (HLA; in humans) complex. T cells bind these epitopes through
a T cell receptor (TCR) complex on the surface of the T cell. T cell receptors are
heterodimeric structures composed of two types of chains: an a ) and (3 (beta) chain,
or a y (gamma) and r3 (delta) chain. The or chain is encoded by the nucleic acid sequence
located within the on locus (on human or mouse chromosome 14), which also encompasses
the entire 6 locus, and the (3 chain is encoded by the c acid sequence located within
the [3 locus (on mouse chromosome 6 or human chromosome 7). The majority of T cells
have an afz’) TCR; while a ty of T cells bear a yo TCR. lnteractions of TCRs with MHC
class l (presenting to CD8+ T cells) and MHC class ll (presenting to CD4+ T cells)
molecules are shown in (closed symbols represent non-human sequences; open
s represent human ces, showing one particular embodiment of the TCR
protein of the present invention).
T cell receptor or and [3 polypeptides (and similarly y and 6 polypeptides) are
linked to each other via a disulfide bond. Each of the two polypeptides that make up the
TCR contains an extracellular domain sing nt and variable regions, a
transmembrane domain, and a cytoplasmic tail (the transmembrane domain and the
cytopiasmic tail also being a part of the constant ). The variable region of the TCR
determines its antigen specificity, and similar to immunoglobulins, comprises 3
complementary determining regions (CDRs). Also similar to immunoglobulin genes, T cell
receptor variable gene loci (e.g., TCRoc and TCRB loci) contain a number of unrearranged
V(D)J segments (variable (V), joining (J), and in TCRB and 6, diversity (D) segments).
During T cell development in the thymus, TCRa le gene locus undergoes
rearrangement, such that the resultant TCR a chain is encoded by a specific combination of
VJ segments (Va/Jon ce); and TCRB variable gene locus undergoes rearrangement,
such that the resuitant TCR {3 chain is encoded by a specific combination of VDJ segments
(Vfi/DB/st sequence).
interactions with thymic stroma trigger thymocytes to undergo several
developmental stages, terized by expression of various cell surface markers. A
summary of characteristic cell surface markers at various developmental stages in the
thymus is presented in Table 1. Rearrangement at the TCRB variable gene locus begins at
the DN2 stage and ends during the DN4 stage, while rearrangement of the TCRa variable
gene locus occurs at the DP stage. After the completion of TCRB iocus ngement, the
cells express TCRB chain at the cell surface together with the ate 0t chain, qu. See,
Janeway’s bioiogy, Chapter 7, supra.
Table 1: Developmental Stages of T cells in the Thymus
“"rWhiDevelopmental
CD44+ICD25~ CD44+ICD25+ CD44 °wIC025+ CD44-l CD4+/008+ CD4+
CD25- or
CD8+
Naive CD4+ and CD8+ T cells exit the thymus and enter the peripheral lymphoid
organs (e.g., spleen) where they are exposed to antigens and are activated to ly
expand and entiate into a number of effector T cells (Teff), e.g., xic T celis, TREG
cells, TH17 cells, TH1 celis, TH2 cells, etc. Subsequent to infection, a number ofT cells
persist as memory T cells, and are classified as either central memory T cells (Tcm) or
effector memory T ceils (Tern). Sallusto et ai. (1999) Two subsets of memory T lymphocytes
with distinct homing potentials and effector functions, Nature 401:708—12 and Commentary
by Mackay (1999) Dual personality of memory T cells, Nature 401:659-60. Sallusto and
colleagues proposed that, after initial infection, Tem cells represent a readily available pool
of antigen—primed memory T cells in the peripheral tissues with effector functions, while Tcm
cells represent antigen-primed memory T cells in the peripheral lymphoid organs that upon
secondary challenge can become new effector T cells. While all memory T cells express
CD45RO m of CD45 (naive T cells express CD45RA m), Tcm are characterized
by expression of L-selectin (also known as CD62L) and CCR7+, which are important for
binding to and signaling in the peripheral lymphoid organs and lymph nodes. Id. Thus, all T
cells found in the peripheral lymphoid organs (e.g., naive T cells, Tcm cells, etc.) express
CD62L. in on to CD45RO, all memory T cells are known to express a number of
ent cell surface markers, e.g., CD44. For y of various cell surface markers on
T cells, see Janeway’s lmmunobiology, Chapter 10, supra.
While TCR variable domain functions primarily in antigen recognition, the
extracellular portion of the constant , as well as transmembrane, and asmic
domains of the TCR also serve important functions. A complete TCR receptor complex
requires more than the a and [3 or y and 5 polypeptides; additional molecules required
include CD3], CD36, and CD35, as well as the C chain homodimer (it). At the completion of
TCRB rearrangement, when the cells express TCRB/pTa, this pre-TCR complex exists
together with CD3 on the cell surface. TCRoc (or pToc) on the cell surface has two basic
residues in its transmembrane , one of which recruits a CD3ys heterodimer, and
another recruits t]; via their respective acidic residues. TCRB has an additional basic
residue in its transmembrane domain that is believed to recruit CD365 dimer. See,
e.g., Kuhns et al. (2006) tructing the Form and Function of the TCR/CD3 Complex,
immunity 24:133-39; pfennig et al. (2009) Structural y of the T-cell Receptor:
Insights into Receptor Assembly, Ligand Recognition, and tion of Signaling, Cold Spring
Harb. Perspect. Biol. 2:a005140. The assembled complex, comprising TCRocfs heterodimer,
CD3ys, CD352, and 2;; is expressed on the T cell e. The polar residues in the
transmembrane domain have been suggested to serve as quality l for exiting
endoplasmic reticulum; it has been demonstrated that in the absence of CD3 subunits, TCR
chains are retained in the ER and targeted for degradation. See, e.g., Call and
Wucherpfennig (2005) The T Cell Receptor: Critical Role of the Membrane Environment in
Receptor Assembly and Function, Annu. Rev. lmmunol. 23:101—25.
CD3 and C chains of the assembled complex provide components for TCR
signaling as TCRocB heterodimer (or TCRyt‘) heterodimer) by itself lacks signal transducing
activity. The CD3 chains possess one lmmune-Receptor-Tyrosine-based-Activation-Motif
(lTAM) each, while the 2; chain contains three tandem lTAMs. ITAMs contain tyrosine
residues capable of being phosphorylated by associated kinases, Thus, the led
3 complex ns 10 lTAM . See, e.g., Love and Hayes (2010) lTAM-
Mediated Signaling by the T—Cell Antigen Receptor, Cold Spring Harb. Perspect. Biol.
21e002485. Following TCR engagement, lTAM motifs are orylated by Src family
tyrosine kinases, Lck and Fyn, which tes a signaling cascade, resulting in Ras
activation, calcium mobilization, actin cytoskeleton rearrangements, and activation of
transcription factors, all tely leading to T cell differentiation, proliferation, and effector
actions. Id., see also, Janeway’s lmmunobiology, 7th Ed., Murphy et al. eds., Garland
Science, 2008; both incorporated herein by reference.
onally, TCRB transmembrane and cytoplasmic domains are thought to have
a role in mitochondrial targeting and induction of apoptosis; in fact, naturally occurring N-
terminally truncated TCRB molecules exist in thymocytes. Shani et al. (2009) lncompiete T—
cell receptor-—B peptides target the mitochondrion and induce sis, Blood 113:3530-41.
Thus, several ant functions are served by the TCR constant region (which, in various
embodiments, comprises a portion of extracellular as well as transmembrane and
cytoplasmic domains); and in various embodiments the structure of this region should be
taken into consideration when designing humanized TCRs or genetically modified non-
human animals expressing the same.
Mice transgenic for rearranged T cell receptor sequences are known in the art.
The present invention relates to genetically modified non—human animals (e.g., rodents, e.g.,
rats, mice) that comprise unrearranged human or zed T cell variable gene loci that
are capable of rearranging to form nucleic acid sequences that encode human T cell
receptor variable domains, including animals that comprise T cells that comprise rearranged
human le domains and non-human (e.g., mouse or rat) constant s. The present
ion also provides non-human animals (e.g., rodents, e.g., rats, mice) that are e
of generating a diverse repertoire of human T cell receptor variable region sequences; thus,
the present invention provides non-human animals that express TCRs with fully human
le domains in response to an antigen of interest and that bind an e of the
antigen of interest. In some embodiments, provided are non-human animals that generate a
diverse T cell receptor repertoire capable of reacting with various antigens, including but not
limited to antigens presented by APCs.
ln one embodiment, the invention provides cally modified non-human
animals (e.g., rodents, e.g., rats, mice) that comprise in their genome unrearranged human
TCR le region segments (V(D)J segments), wherein the unrearranged human TCR
variable region segments replace, at an endogenous non-human (e.g., rodent) TCR variable
gene locus (e.g., TCRa, f3, 5, and/or y variable gene locus), endogenous non—human TCR
variable region segments. in one embodiment, unrearranged human TCR variable gene
locus replaces endogenous non-human TCR variable gene locus.
in another embodiment, the invention provides cally modified non-human
animals (e.g., rodents, e.g., rats, mice) that comprise in their genome unrearranged human
TCR variable region segments (V(D)J segments), n the unrearranged human TCR
variable region segments are operably linked to a non-human TCR constant region gene
sequence resulting in a humanized TCR locus, wherein the humanized TCR locus is at a
site in the genome other than the endogenous non-human TCR locus. Thus, in one
ment, a non—human animal (e.g., rodent, e.g., mouse, rat) comprising a transgene
that comprises unrearranged human TCR variable region segments ly linked to non-
human TCR constant region sequence is also ed.
in one aspect, the genetically modified non-human animals of the invention
comprise in their genome human TCR variable region ts, while ing non—human
(e.g., , e.g., mouse, rat) TCR constant gene segments. in various embodiments,
constant s include transmembrane domain and the cytoplasmic tail of the TCR. Thus,
in various ments of the present invention, the genetically modified non-human
animals retain endogenous non-human TCR transmembrane domain and asmic tail.
In other embodiments, non—human animals comprise non—human non—endogenous TCR
constant gene ces, e.g., non-human non-endogenous TCR transmembrane domain
and cytoplasmic tail. As indicated above, the constant region of the TCR participates in a
signaling e initiated during antigen-primed T cell activation; thus, endogenous TCR
constant region cts with a variety of non-human anchor and signaling proteins in the T
cell. Thus, in one aspect, the genetically modified non-human animals of the invention
express zed T cell receptors that retain the ability to recruit a variety of endogenous
non—human anchor or signaling molecules, e.g., CD3 molecules (e.g., CD3y, C036, CD32),
the C chain, Lck, Fyn, ZAP-70, etc. A nonlimiting list of molecules that are recruited to the
TCR complex is described in Janeway’s lmmunobiology, supra. In addition, similar to
VELOClMMUNE® mice, which exhibit normal B cell development and normal clonal
selection processes believed to be due at least in part to the placement of le regions
at the endogenous mouse loci and the maintenance of mouse constant domains, in one
aspect, the non-human animals of the present invention exhibit normal T cell development
and T cell differentiation processes.
In some embodiments, a non-human animal is provided that comprises in its
genome unrearranged human TCRa variable region segments, wherein the unrearranged
human TCRoc variable region segments are operably linked to a non-human TCRoc constant
region gene sequence resulting in a humanized TCRoc locus. in one embodiment, the
humanized TCRa locus is at a site in the genome other than the endogenous non—human
TCRa locus. in another embodiment, the unrearranged human TCRoc variable region
segments e endogenous non-human TCRoc variable region segments while ing
endogenous non-human TCRoc constant region. ln one embodiment, the unrearranged
human TCRor le gene locus replaces endogenous non-human TCRa variable gene
locus. in some embodiments, the animal retains endogenous non-human TCRfi le
region and constant region gene sequences. Thus, the animal expresses a TCR that
comprises a chimeric non-human (i.e., humanized) TCRa chain and a non-human
TCRB chain.
in other embodiments, a non-human animal is provided that comprises in its
genome unrearranged human TCRB variable region segments, wherein the unrearranged
human TCRfi le region segments are operably linked to a non-human TCRB constant
region gene ce resulting in a humanized TCRB locus. In one embodiment, the
humanized TCRE locus is at a site in the genome other than the nous non-human
TCRB locus. ln another ment, the unrearranged human TCRB variable region
segments replace endogenous non-human TCRB variable region segments while ing
endogenous non-human TCRB constant region. in one embodiment, the unrearranged
human TCRB le gene locus replaces endogenous non-human TCRB variable gene
locus. In some embodiments, the animal retains endogenous non—human TCRa variable
region and constant region gene sequences. Thus, the animal expresses a TCR that
comprises a chimeric human/non—human (i.e., humanized) TCRB chain and a non-human
TCRoc chain.
in some specific embodiments, the invention provides a genetically modified non—
human animal (e.g., rodent, e.g., mouse or rat) that comprises in its genome (a) an
unrearranged T cell receptor (TCR) on variable gene locus comprising at least one human Va
t and at least one human Jor segment, operably linked to an endogenous non-
human (e.g., rodent, e.g., mouse or rat) TCRa constant gene sequences, and/or (b) an
unrearranged TCRB variable gene locus sing at least one human VB segment, at
least one human D5 segment, and at least one human JB t, operably linked to an
endogenous non—human (e.g., rodent, e.g., mouse or rat) TCRffi constant gene sequence.
In various embodiments of the invention, the unrearranged human or humanized
TCR variable gene locus (e.g., TCRa and/or TCRfi variable gene locus gene locus) is
comprised in the germline of the non—human animal (e.g., rodent, e.g., mouse or rat). in
various ments, the replacements of TCR V(D)J segments by unrearranged human
TCR V(D)J segments (e.g., V0: and Jet, and/or VB and DB and J6 segments) are at an
nous non-human TCR variable locus (or loci), wherein the unrearranged human V
and J and/or V and D and J segments are operably linked to non-human TCR constant
region genes.
ln some embodiments of the invention, the non-human animal comprises two
copies of the unrearranged human or humanized TCRoc variable gene locus and/or two
copies of the unrearranged human or humanized TCRB variable gene locus. Thus, the non-
human animal is homozygous for one or both unrearranged human or humanized TCRor and
TCRIB variable gene locus. in some embodiments of the invention, the non—human animal
comprises one copy of the unrearranged human or humanized TCRor variable gene locus
and/or one copy of the unrearranged human or humanized TCRiS variable gene locus.
Thus, the non-human animal is heterozygous for one or both unrearranged human or
humanized TCRor and TCRfi variable gene locus.
In one embodiment, the unrearranged TCRa variable gene locus sing
human variable region segments (e.g., human Va and Jet ts) is positioned in the
non-human genome such that the human variable region segments replace corresponding
non-human le region segments. In one embodiment, the unrearranged TCRa variable
gene locus comprising human variable region segments replaces endogenous TCRa
variable gene locus. In one aspect, endogenous non-human Va and Jon ts are
incapable of rearranging to form a rearranged VOL/Jot ce. Thus, in one aspect, the
human Va and Ja segments in the ranged TCRor variable gene locus are capable of
rearranging to form a rearranged human Vor/Jor ce.
Similarly, in one embodiment, the unrearranged TCRB le gene locus
comprising human variable region ts (e.g., human VB, DB, and JB segments) is
positioned in the non—human genome such that the human variable region segments replace
corresponding non-human variable region segments. In one embodiment, the unrearranged
TCRfS variable gene locus comprising human variable region segments replaces
endogenous TCRfi variable gene locus. in one aspect, endogenous non-human V13, DB,
and JB segments are incapable of rearranging to form a rearranged VB/DB/JB sequence.
Thus, in one aspect, the human V13, DB, and Jfi segments in the unrearranged TCRB
variable gene locus are capable of rearranging to form a rearranged human VqB/DB/Jfi
sequence.
In yet another embodiment, both the unrearranged TCRa and B variable gene
loci sing human variable region segments replace respective endogenous TCRa and
[3 variable gene loci. In one aspect, endogenous non—human Va and Jet segments are
incapable of rearranging to form a rearranged Voc/Joc sequence, and endogenous non—
human VB, DB, and J13 segments are incapable of rearranging to form a rearranged
Vfi/DB/Jfi sequence. Thus, in one aspect, the human Vor and Ja segments in the
unrearranged TCRa variable gene locus are capable of rearranging to form a rearranged
human Von/Jon sequence and the human V6, DE», and JB ts in the unrearranged
TCRfi le gene locus are capable of rearranging to form a rearranged human
Vafi/Dfi/JB sequence.
In some aspects of the invention, the non—human animal comprising a humanized
TCRq and/or TCRfi gene locus (comprising an unrearranged TCRa and/or TCRfi variable
gene locus) retains an endogenous non-human TCRa and/or TCRB variable gene locus. In
one embodiment, the endogenous non—human TCRa and/or TCRfS variable gene locus is a
non—functional locus. In one embodiment, the non-functional locus is an vated locus,
e.g., an ed locus (e.g., the coding nucleic acid sequence of the variable gene locus is
in inverted orientation with t to the constant region sequence, such that no successful
rearrangements are possible utilizing variable region segments from the inverted locus). In
one embodiment, the zed TCRa and/or TCRB variable gene locus is positioned
between the endogenous non-human TCRoc and/or TCRB variable gene locus and the
endogenous man TCRa and/or TCRfi constant gene locus.
The number, nomenclature, position, as well as other aspects of V and J and/or
V, D, and J segments of the human and mouse TCR loci may be ascertained using the
lMGT database, available at www.imgt.org. The mouse TCRq variable locus is
approximately 1.5 megabases and ses a total of 110Va and 60 Jet segments (.
The human TCRor variable locus is approximately 1 megabase and comprises a total of
54Va and 61Ja segments, with 45Va and 50Ja believed to be functional. Unless stated
otherwise, the numbers; of human V(D)J segments referred to hout the ication
refers to the total number of V(D)J segments. In one embodiment of the invention, the
genetically modified non-human animal (e.g., rodent, e.g., mouse or rat) ses at least
one human Va and at least one human Jo: segment. In one ment, the non-human
animal comprises a humanized TCRoc locus that comprises 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 15,
2012/062065
, 23, 25, 30, 35, 40, 45, 48, 50, or up to 54 human Va segments. In some embodiments,
the zed TCRa locus comprises 2, 8, 23, 35, 48, or 54 human Va segments. Thus, in
some embodiments, the humanized TCRa locus in the non—human animal may comprise
%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98% 99%, or 100% of human Va; in some embodiments, it may
comprise about 2%, about 3%, about 15%, about 65%, about 90%, or 100% of human Va.
In one embodiment, the non-human animal comprises a humanized TCRa locus
that comprises a DNA fragment sing a contiguous human sequence of human Va40
to Va41 (Va segment is also referred to as “TRAV” or “TCRAV”) and a DNA fragment
comprising a contiguous human sequence of 61 human Ja segments (Ja segment is also
referred to as “TRAJ” or “TCRAJ”). in one embodiment, the non—human animal comprises a
humanized TCRa locus that comprises a DNA fragment comprising a contiguous human
sequence of human TRAV35 to TRAV41 and a DNA fragment comprising a contiguous
human sequence of 61 human TRAJs. in one embodiment, the non-human animal
comprises a humanized TCRa locus that comprises a DNA nt comprising a
contiguous human ce of human TRAV22 to TRAV41 and a DNA fragment comprising
a contiguous human sequence of 61 human TRAJs. in one embodiment, the non-human
animal comprises a humanized TCRa locus that comprises a DNA fragment comprising a
contiguous human sequence of human TRAV13-2 to TRAV41 and a DNA fragment
comprising a contiguous human sequence of61 human TRAJs. in one embodiment, the
non—human animal comprises a humanized TCRa locus that ses a DNA fragment
comprising a contiguous human sequence of human TRAV6 to TRAV41 and 61 human
TRAJs. in one embodiment, the non-human animal comprises a humanized TCRa locus
that comprises a DNA fragment comprising a contiguous human sequence of human
TRAV1-1 to TRAV 41 and 61 human TRAJs. In s embodiments, the DNA fragments
comprising contiguous human sequences of human TCRa variable region segments also
comprise ction enzyme sites, selection cassettes, endonucleases sites, or other sites
inserted to facilitate cloning and selection during the locus humanization process. In various
embodiments, these additional sites do not interfere with proper functioning (e.g.,
ngement, splicing, etc.) of various genes at the TCRa locus.
in one embodiment, the humanized TCRa locus comprises 61 human Ja
segments, or 100% of human Ja ts. in a particular embodiment, humanized TCRa
locus ses 8 human Va segments and 61 human Ja segments; in another particular
embodiment, humanized TCRa locus ses 23 human Va segments and 61 human Ja
segments. in another particular embodiment, the humanized TCRa locus comprises a
te repertoire of human Va and Jon segments, i.e., all human variable on region gene
segments d by the oz locus, or 54 human Von and 61 human Ja segments. in various
embodiments, the non-human animal does not comprise any endogenous non-human Va or
Joc ts at the TCRq locus.
The mouse TCRffi variable locus is approximately 0.6 megabases and comprises
a total of 33 V6, 2 DB, and 14 J6 segments (. The human TCRB variable locus is
approximately 0.6 megabases and comprises a total of 67 VB, 2 DB, and 14 J6 segments.
In one embodiment of the invention, the genetically modified non—human animal (e.g.,
rodent, e.g., mouse or rat) comprises at least one human V6, at least one human D8, and at
least one human Ja segment. In one embodiment, the non-human animal ses a
humanized TCRfi locus that comprises 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 15, 20, 23, 25, 30, 35,40,
45, 48, 50, 55, 60, or up to human 67 V6 segments. In some embodiments, the humanized
TCRfS locus comprises 8, 14, 40, 66, or human 67 V6 ts. Thus, in some
embodiments, the humanized TCRfi locus in the non-human animal may comprise 5%, 10%,
%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98% 99%, or 100% of human V6; in some embodiments, it may comprise
about 20%, about 60%, about 15%, about 98%, or 100% of human V6.
in one embodiment, the non-human animal comprises a humanized TCRfi locus
that comprises a DNA fragment comprising a uous human sequence of human V618
to V6294 (VB segment is also referred to as “TRBV” or “TCRBV”). in one embodiment, the
man animal comprises a humanized TCRB locus that comprises a DNA fragment
comprising a contiguous human sequence of human TRBV18 to -1, a separate DNA
fragment comprising a contiguous human sequence of human Dfi1-Ji31 (i.e., human D91-
Jf31Jf51-6 segments), and a separate DNA fragment sing a contiguous human
sequence of human z (i.e., human DBZ-J62-1—J62—7 segments). in one embodiment,
the non—human animal comprises a humanized TCRfi locus that comprises a DNA fragment
comprising a contiguous human sequence of human TRBV6-5 to TRBV29-1, a separate
DNA fragment comprising a contiguous human sequence of human D61-JB1 (i.e., human
DB1-Jl31Jf31-6 segments), and a separate DNA fragment comprising a uous human
sequence of human DBZ—JfiZ (i.e., human D62-JBZJ62-7 ts). in one embodiment,
the non-human animal comprises a humanized TCRB locus that comprises a DNA fragment
comprising a contiguous human sequence of human TRBV1 to TRBV29—1, a separate DNA
fragment comprising a uous human sequence of human DB1—Jf31, and a separate
DNA fragment comprising a contiguous human sequence of human DB2—JB2. In one
ment, the man animal comprises a humanized TCRB locus that comprises a
DNA nt comprising a contiguous human sequence of human TRBV1 to TRBV29—1, a
separate DNA fragment comprising a contiguous human ce of human DB1-JB1, a
separate DNA fragment comprising a contiguous human sequence of human DB2—JB2, and
a separate DNA fragment comprising the sequence of human TRBV30. In various
embodiments, the DNA fragments sing contiguous human sequences of human
TCRB variable region segments also se restriction enzyme sites, selection cassettes,
endonucleases sites, or other sites inserted to facilitate cloning and selection during the
locus humanization s. In s embodiments, these additional sites do not interfere
with proper functioning (e.g., rearrangement, splicing, etc.) of various genes at the TCRB
locus.
In one embodiment, the humanized TCRB locus comprises 14 human JB
segments, or 100% of human JB segments, and 2 human DB ts or 100% of human
JB segments. In another embodiment, the humanized TCRB locus ses at least one
human VB segment, e.g., 14 human VB segments, and all mouse DB and JB segments. In a
particular embodiment, humanized TCRB locus ses 14 human VB segments, 2 human
DB segments, and 14 human JB segments. In another particular embodiment, the
humanized TCRB locus comprises a complete repertoire of human VB, DB, and JB
segments, i.e., all human variable B region gene segments encoded by the B locus or 67
human VB, 2 human DB, and 14 human JB segments. In one embodiment, the non-human
animal ses one (e.g., 5’) non-human VB segment at the humanized TCRB locus. In
various embodiments, the non—human animal does not comprise any endogenous non-
human VB, DB, or JB segments at the TCRB locus.
In various embodiments, wherein the non—human animal (e.g., rodent) comprises
a repertoire of human TCRa and TCRB (and optionally human TCRB and TCRy) variable
region segments (e.g., a complete repertoire of variable region segments), the repertoire of
s segments (e.g., the complete oire of various segments) is utilized by the
animal to generate a diverse repertoire of TCR molecules to various antigens.
In various aspects, the non-human animals se contiguous portions of the
human genomic TCR variable loci that comprise V, D, and J, or D and J, or V and J, or V
segments arranged as in an unrearranged human genomic variable locus, e.g., comprising
promoter sequences, leader sequences, intergenic sequences, regulatory sequences, etc.,
ed as in a human genomic TCR variable locus. In other aspects, the various
segments are arranged as in an unrearranged non-human genomic TCR variable locus. in
various ments of the zed TCRa and/or [3 locus, the humanized locus can
comprise two or more human genomic segments that do not appear in a human genome
juxtaposed, e.g., a fragment ofV segments of the human V locus located in a human
genome proximal to the constant region, juxtaposed with a nt of V segments of the
human V locus located in a human genome at the upstream end of the human V locus.
in both mouse and human, the TCRé gene segments are located with the TCRa
locus (see Fle. 2 and 5). TCRo J and D segments are located between VOL and Ja
segments, while TCRB V ts are interspersed throughout the TCRa locus, with the
majority d among various Von segments. The number and locations of various TCRE)
segments can be determined from the lMGT database. Due to the genomic arrangement of
TCRE) gene segments within the TCRoc locus, successful rearrangement at the TCRa locus
generally deletes the TCRB gene ts.
in some embodiments of the invention, a non—human animal comprising an
unrearranged human TCRa variable gene locus also comprises at least one human V5
segment, e.g., up to complete repertoire of human V6 segments. Thus, in some
embodiments, the replacement of endogenous TCRa le gene iocus results in a
replacement of at least one non-human V6 segment with a human V5 segment. in other
embodiments, the non—human animal of the ion comprises a complete repertoire of
human V6, D6, and J6 segments at the unrearranged humanized TCRoc locus; in yet other
embodiments, the non—human animal comprises a complete unrearranged human TCRé
locus at the ranged humanized TCRor locus (Le, a TCRo locus including human
variable region segments, as well as human enhancer and constant region). An exemplary
embodiment for ucting an unrearranged humanized TCRoc locus comprising te
unrearranged TCRo locus is depicted in
In yet another embodiment, the non—human animal of the invention further
comprises an unrearranged humanized TCRy locus, e.g., a TCRy locus comprising at least
one human Vy and at least one human Jy segments (e.g., a complete repertoire of human
Vy and human Jy variable region segments). The human TCRy locus is on human
chromosome 7, while the mouse TCRy locus is on mouse chromosome 13. See the lMGT
database for more detail on the TCRy locus.
in one aspect, the non-human animal (e.g., rodent, e.g., mouse or rat) comprising
humanized TCRoc and [3 variable gene loci (and, optionally humanized TCRB/y variable gene
loci) described herein ses a humanized T cell receptor comprising a human variable
region and a non-human (e.g., rodent, e.g., mouse or rat) constant region on a surface of a
T cell. ln some aspects, the non-human animal is e or expressing a e repertoire
of zed T cell receptors that recognize a y of presented antigens.
In various embodiments of the invention, the humanized T cell receptor
polypeptides described herein se human leader sequences. in alternative
embodiments, the humanized TCR receptor nucleic acid sequences are engineered such
that the humanized TCR ptides comprise non—human leader sequences.
The zed TCR polypeptides bed herein may be expressed under
control of endogenous non-human regulatory elements (e.g., rodent regulatory elements),
e.g., promoter, silencer, enhancer, etc. The humanized TCR polypeptides described herein
may alternatively be expressed under control of human regulatory elements. In various
embodiments, the non—human animals described herein further comprise all tory and
other ces normally found in situ in the human genome.
in various embodiments, the human variable region of the humanized TCR
protein is capable of interacting with various proteins on the surface of the same cell or
another cell. in one embodiment, the human variable region of the humanized TCR
interacts with MHC proteins (e.g., MHC class I or ll proteins) ting antigens on the
surface of the second cell, e.g., an antigen presenting cell (APC). in some embodiments,
the MHC l or ll n is a non-human (e.g., rodent, e.g., mouse or rat) protein. In other
embodiments, the MHC l or ll protein is a human protein. In one aspect, the second cell,
e.g., the APC, is an endogenous non-human cell expressing a human or humanized MHC
molecule. ln a different embodiment, the second cell is a human cell expressing a human
MHC molecule.
In one aspect, the non—human animal expresses a humanized T cell receptor with
a non—human constant region on the surface of a T cell, wherein the receptor is capable of
interacting with non-human les, e.g., anchor or signaling molecules sed in the
T cell (e.g., CD3 molecules, the C, chain, or other proteins ed to the TCR through the
CD3 molecules or the C .
Thus, in one aspect, a cellular complex is provided, comprising a non—human T-
cell that expresses a TCR that comprises a humanized TCRa chain as described herein and
humanized TCR[5 chain as described herein, and a non-human antigen-presenting cell
comprising an antigen bound to an MHC l or MHC ll. in one embodiment, the non-human
nt TCch and TCRB chains are complexed with a non-human zeta (C) chain
homodimer and CD3 heterodimers. in one embodiment, the cellular complex is an in vivo
cellular complex. in one embodiment, the cellular complex is an in vitro cellular complex.
] The genetically modified non—human animal may be selected from a group
consisting of a mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat,
chicken, cat, dog, ferret, primate (e.g., marmoset, rhesus monkey). Forthe non—human
animals where suitable genetically modifiable ES cells are not y available, other
methods are employed to make a non—human animal sing the genetic modification.
Such methods include, e.g., modifying a non—ES cell genome (e.g., a fibroblast or an
induced pluripotent cell) and employing nuclear transfer to transfer the modified genome to a
suitable cell, e.g., an oocyte, and gestating the modified cell (e.g., the modified oocyte) in a
non-human animal under suitable conditions to form an embryo.
In one aspect, the non-human animal is a mammal. ln one aspect, the nonhuman
animal is a small , e.g., of the superfamily Dipodoidea or Muroidea. in one
embodiment, the genetically modified animal is a rodent. In one embodiment, the rodent is
selected from a mouse, a rat, and a hamster. In one ment, the rodent is selected
from the superfamily Muroidea. ln one embodiment, the genetically ed animal is from
a family selected from Calomyscidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamster,
New World rats and mice, voles), Muridae (true mice and rats, gerbils, spiny mice, crested
rats), Nesomyidae (climbing mice, rock mice, with-tailed rats, Malagasy rats and mice),
Platacanthomyidae (e.g., spiny dormice), and Spalacidae (e.g., mole rates, bamboo rats,
and zokors). ln a specific embodiment, the cally modified rodent is selected from a
true mouse or rat (family e), a gerbil, a spiny mouse, and a crested rat. ln one
ment, the genetically modified mouse is from a member of the family Muridae. In
one embodiment, the animal is a rodent. In a specific embodiment, the rodent is selected
from a mouse and a rat. ln one embodiment, the non—human animal is a mouse.
In a specific embodiment, the non-human animal is a rodent that is a mouse of a
CS7BL strain selected from C57BL/A, CS7BL/An, GrFa, C57BL/KaLwN, CS7BL/6,
C57BL/6J, CS7BL/6ByJ, CS7BL/6NJ, C57BL/10, CS7BL/108c8n, C57BL/1OCr, and
Ola. in another embodiment, the mouse is a 129 strain selected from the group
consisting ofa strain that is 129P1, 129P2, 129P3, 129X1, 12981 (e.g., 12981/8V,
12981/8vlm), 12982, 12984, 12985, SvaH, 12986 (129/SvaTac), 12987, 12988,
129T1, 129T2 (see, e.g., Festing et al. (1999) Revised nomenclature for strain 129 mice,
Mammalian Genome 10:836, see also, Auerbach et al (2000) Establishment and a
is of 129/8va- and C57BL/6—Derived Mouse Embryonic Stem Cell Lines). ln a
specific embodiment, the genetically modified mouse is a mix of an entioned 129
strain and an aforementioned CS7BL/6 strain. In another specific embodiment, the mouse is
a mix of aforementioned 129 strains, or a mix of aforementioned BL/6 s. In a specific
embodiment, the 129 strain of the mix is a 12986 (129/8vaTac) strain. In another
embodiment, the mouse is a BALB strain, e.g., BALB/c strain. in yet another embodiment,
the mouse is a mix of a BALB strain and another aforementioned strain.
in one ment, the non-human animal is a rat. in one embodiment, the rat
is selected from a Wistar rat, an LEA , a Sprague Dawley strain, a Fischer strain, F344,
F6, and Dark Agouti. in one embodiment, the rat strain is a mix of two or more strains
selected from the group consisting of Wistar, LEA, Sprague Dawley, Fischer, F344, F6, and
Dark .
Thus, in one embodiment, the ion provides a genetically modified mouse
sing in its genome an unrearranged human or humanized TCR variable gene locus,
e.g., TCRa, TCRB, TCRB, and/or TCRy variable gene locus. in some embodiments, the
unrearranged human or humanized TCR variable gene locus replaces endogenous mouse
TCR variable gene locus. in other embodiments, unrearranged human or humanized TCR
variable gene locus is at a site in the genome other than the corresponding endogenous
mouse TCR locus. in some embodiments, human or humanized unrearranged TCR variable
gene locus is operably linked to mouse TCR constant region.
in one embodiment, a genetically modified mouse is provided, wherein the
mouse comprises in its genome an unrearranged T cell receptor (TCR) 0: le gene
locus comprising at least one human Joc segment and at least one human Va segment,
operably linked to a mouse TCRa constant gene sequence, and an unrearranged TCRB
variable gene locus comprising at least one human JB segment, at least one human DB
segment, and at least one human VB segment, operably linked to a mouse TCRB constant
gene sequence. In one ic embodiment, the mouse ses in its genome an
unrearranged TCRa le gene locus comprising a complete oire of human Ja
segments and a complete repertoire of human Von segments, operably linked to a mouse
TCRoc constant gene sequence, and an unrearranged TCRB variable gene locus comprising
a complete repertoire of human JB ts, a complete repertoire of human DB segments,
and a complete repertoire of human VB segments, operably linked to a mouse TCRB
constant gene sequence.
in some ments, the unrearranged TCRa variable gene locus comprising
human TCRa variable region segments replaces endogenous mouse TCRa variable gene
locus, and the unrearranged TCRB variable gene locus comprising human TCRB variable
region segments replaces the endogenous mouse TCRB le gene locus. In some
embodiments, the endogenous mouse Va and Jo: segments are incapable of rearranging to
form a rearranged VOL/Jet sequence, and the endogenous mouse VB, DB, and JB segments
are incapable of rearranging to form a rearranged /JB sequence. in some
embodiments, the human V0: and Jet segments rearrange to form a rearranged human
Von/Jo: sequence, and the human VB, DB, and J0 segments rearrange to form a rearranged
human VB/DB/JB sequence.
In various embodiments, the non-human animals (e.g., s, e.g., mice or
rats) described herein produce T cells that are capable of undergoing thymic development,
ssing from DN1 to DN2 to DN3 to DN4 to DP and to CD4 or CD8 SP T cells. Such T
cells of the non-human animal of the invention express cell e molecules typically
produced by a T cell during a particular stage of thymic development (e.g., CD25, CD44, Kit,
CD3, pToc, etc.). Thus, the non-human animals described herein express pToc complexed
with TCRB at the DN3 stage of thymic development. The non—human animals described
herein express T cells capable of undergoing thymic development to produce CD4+ and
CD8+ T cells. Normally, in the thymus the physiological ratio of CD4+ to CD8+ T cells is
between about 2:1 and 321. See, e.g., Ge and Stanley (2008) The O-fucose glycan in the
ligand-binding domain of Notch 1 regulates embryogenesis and T cell development, Proc.
Natl. Acad. Sci. USA 105:1539-44. Thus, in one embodiment, the man s
bed herein produce CD4+ and CD8+ T cells in the thymus at a ratio of between about
2:1 and 3:1 (CD4+:CD8+).
in various embodiments, the non—human animals described herein produce T
cells that are capable of undergoing normal T cell differentiation in the periphery. In some
embodiments, the non—human animals described herein are capable of producing a normal
repertoire of effector T cells, e.g., CTL (cytotoxic T lymphocytes), TH1, TH2, TREg, TH17, etc.
Thus, in these embodiments, the non—human animals described herein te effector T
cells that fulfill different ons l of the particularT cell type, e.g., recognize, bind,
and respond to foreign antigens. In various embodiments, the non-human animals
described herein produce effector T cells that kill cells displaying peptide nts of
cytosolic pathogens expressed in the context of MHC l molecules; recognize peptides
derived from antigens degraded in intracellular vesicles and presented by MHC ll molecules
on the surface of macrophages and induce macrophages to kill microorganisms; e
cytokines that drive B cell differentiation; activate B cells to produce opsonizing antibodies;
induce lial cells to produce chemokines that t neutrophils to infection sites; etc.
ln onal embodiments, the non-human animals described herein comprise a
normal number of CD3+ T cells in the periphery, e.g., in the spleen. In some embodiments,
the percent of peripheral CD3+ T cells in the non—human animals described herein is the
comparable to that of the wild type animals (i.e., animals comprising all endogenous TCR
2012/062065
variable region segments). In one embodiment, the non—human animals described herein
comprise a normal ratio of splenic CD3+ T cells to total splenocytes.
in other aspects, the non-human animals described herein are capable of
ting a population of memory T cells in response an antigen of st. For example,
the non—human animals generate both central memory T cells (Tcm) and effector memory T
cells (Tern) to an antigen, e.g., antigen of interest (e.g., antigen being tested for vaccine
development, etc.).
DN1 and DN2 cells that do not receive sufficient signals (e.g., Notch signals) may
develop into B cells, myeloid cells (e.g., dendritic cells), mast cells and NK cells. See, e.g.,
Yashiro-Ohtani et al. (2010) Notch regulation of early thymocyte pment, Seminars in
immunology 222261—69. in some embodiments, the non-human animals described herein
develop normal numbers of B cells, myeloid cells (e.g., dendritic cells), mast cells and NK
cells. In some embodiments, the man s described herein develop normal
dendritic cell population in the thymus.
The predominant type of T cell receptors expressed on the surface of T cells is
TCRa/B, with the minority of the cells expressing TCRé/y. In some embodiments of the
invention, the T cells of the non—human animals comprising humanized TCRoc and/or [3 loci
exhibit normal utilization of TCRoc/B and TCRa/y loci, e.g., utilization of TCRoc/{S and TCRé/y
loci that is r to the wild type animal (e.g., the T cells of the non—human animals
described herein express TCRa/B and TCRtS/y ns in comparable proportions to that
expressed by wild type animals). Thus, in some embodiments, the non-human animals
comprising humanized TCRoc/B and endogenous non—human TCRé/y loci exhibit normal
utilization of all loci.
In addition to genetically engineered non-human animals described herein, a
non-human embryo (e.g., a rodent embryo, e.g., mouse or a rat embryo) is also ed,
wherein the embryo comprises a donor ES cell that is d from a non-human animal
(e.g., a rodent, e.g., a mouse or a rat) as described herein. in one aspect, the embryo
comprises an E8 donor cell that comprises an unrearranged humanized TCR locus, and
host embryo cells.
Also ed is a tissue, wherein the tissue is derived from a man animal
(e.g., a mouse or a rat) as described , and expresses a humanized TCR polypeptide
(e.g., TCRoc and/or TCRB, or TCRé, and/or TCRy polypeptide).
In addition, a non—human cell isolated from a non—human animal as described
herein is provided. in one embodiment, the cell is an ES cell. in one embodiment, the cell is
a T cell. In one embodiment, the T cell is a CD4+ T cell. in r embodiment, the T cell
is a CD8+ T cell.
Also provided is a non-human cell comprising a chromosome or fragment thereof
of a non-human animal as described herein. In one embodiment, the non—human cell
comprises a nucleus of a non-human animal as described herein. in one embodiment, the
non—human cell comprises the chromosome or fragment thereof as the result of a nuclear
transfer.
Also provided is a man cell that expresses a TCR protein comprising a
human variable region and a non-human nt region. The TCR protein may comprise
TCRa, TCRB, or a combination thereof. In one embodiment, the cell is a T cell, e.g., a
CD4+ or a CD8+ T cell.
In one aspect, a man induced pluripotent cell comprising an unrearranged
humanized TCR locus encoding a humanized TCR polypeptide as described herein is
provided. In one ment, the d pluripotent cell is derived from a man
animal as described herein.
in one aspect, a hybridoma or quadroma is provided, derived from a cell of a
non-human animal as described herein. in one embodiment, the non-human animal is a
rodent, e.g., a mouse or rat.
Also provided is a method for making a genetically modified non-human animal
(e.g., rodent, e.g., mouse or rat) described . The method for making a genetically
modified man animal results in the animal whose genome comprises a zed
unrearranged TCR locus (e.g., a humanized unrearranged TCRa, TCRfi, TCRé, and/or
TCRy locus). in one embodiment, a method for making a genetically modified non—human
animal (e.g., rodent, e.g., mouse or rat) that expresses a T cell receptor comprising a human
variable region and a non-human (e.g., rodent, e.g., mouse or rat) constant region on a
surface of a T cell is ed, wherein the method comprises replacing in a first non—human
animal an endogenous non—human TCRa variable gene locus with an unrearranged
humanized TCRoc variable gene locus comprising at least one human Va t and at
least one human Jot segment, wherein the zed TCRa variable gene locus is ly
linked to endogenous TCRa constant region; replacing in a second non-human animal an
endogenous non-human TCRfi variable gene locus with an unrearranged humanized TCRB
variable gene locus comprising at least one human VB segment, one human DB segment,
and one human JB segment, wherein the humanized TCRB variable gene locus is operably
linked to endogenous TCRB constant region; and breeding the first and the second non-
WO 63361
human animal to obtain a non—human animal that expresses a T cell receptor comprising a
human variable region and a non—human constant region. In other embodiments, the
invention provides methods of making a genetically modified non—human animal whose
genome comprises a humanized unrearranged TCRa locus, or a non-human animal whose
genome comprises a humanized unrearranged TCRB locus, generated according to the
methods described herein. In various embodiments, the replacements are made at the
endogenous loci. In some embodiments, the method utilizes one or more targeting
constructs made using VELOCIGENE® technology, introducing the construct(s) into ES
cells, and introducing targeted ES cell clones into a mouse embryo using VELOCIMOUSE®
technology, as described in the Examples. In some embodiments, the ES cells are derived
from a mouse that is a mix of 129 and C57BL/6 strains. In various embodiments, the
method comprises ssive humanization strategy, wherein a construct comprising
additional variable region segments is introduced into ES cells at each subsequent step of
zation, ultimately resulting in a mouse sing a complete repertoire of human
variable region segments (see, e.g., Fle. 3 and 7).
Thus, nucleotide constructs used for generating genetically engineered non-
human animals described herein are also provided. In one , the nucleotide construct
comprises: 5’ and 3’ homology arms, a human DNA fragment comprising human TCR
variable region gene t(s), and a selection cassette flanked by recombination sites.
In one embodiment, the human DNA fragment is a TCRa gene fragment and it comprises at
least one human TCRoc variable region segment. In another embodiment, the human DNA
fragment is a TCRB fragment and it comprises at least one human TCRfi variable region
gene segment. In one , at least one gy arm is a non-human homology arm
and it is homologous to non-human TCR locus (e.g., non—human TCRa or TCRB locus).
A selection cassette is a tide sequence ed into a targeting construct
to facilitate selection of cells (e.g., ES cells) that have integrated the construct of interest. A
number of suitable ion tes are known in the art. Commonly, a selection cassette
enables positive selection in the ce of a particular antibiotic (e.g., Neo, Hyg, Pur, CM,
Spec, etc.) In addition, a selection cassette may be flanked by recombination sites, which
allow deletion of the selection cassette upon treatment with recombinase enzymes.
Commonly used recombination sites are loxP and Frt, recognized by Cre and Flp enzymes,
tively, but others are known in the art.
In one embodiment, the selection cassette is located at the 5’ end the human
DNA fragment. In another embodiment, the selection te is located at the 3’ end of the
human DNA nt. In another embodiment, the selection cassette is located within the
human DNA fragment, e.g., within the human . In another embodiment, the selection
cassette is located at the on of the human and mouse DNA fragment.
] Various exemplary embodiments of the targeting strategy for generating
genetically engineered non-human animals, the constructs, and the ing vectors used
for the same are ted in Fle. 3, 4, 5, 7, and 8.
Upon completion of gene targeting, ES cells or genetically modified non-human
animals are screened to confirm successful incorporation of exogenous nucleotide sequence
of interest or expression of exogenous polypeptide (e.g., human TCR variable region
ts). Numerous techniques are known to those skilled in the art, and include (but are
not limited to) Southern blotting, long PCR, quantitative PCT (e.g., real-time PCR using
®), fluorescence in situ hybridization, Northern blotting, flow try, Western
is, immunocytochemlstry, immunohistochemistry, etc. in one e, non-human
animals (e.g., mice) bearing the genetic modification of interest can be identified by
screening for loss of mouse allele and/or gain of human allele using a modification of allele
assay described in Valenzuela et al. (2003) High—throughput engineering of the mouse
genome coupled with high-resolution sion analysis, Nature Biotech. 21(6):652—659.
Other assays that identify a specific nucleotide or amino acid sequence in the genetically
modified animals are known to those skilled in the art.
The disclosure also provides a method of modifying a TCR variable gene locus
(e.g., TCRoc, TCRB, TCRo, and/or TCRy gene locus) of a non—human animal to express a
humanized TCR protein bed herein. In one embodiment, the invention provides a
method of ing a TCR variable gene locus to express a humanized TCR protein on a
surface of a T cell wherein the method comprises replacing in a non-human animal an
endogenous non-human TCR variable gene locus with an ranged humanized TCR
variable gene locus. In one embodiment wherein the TCR variable gene locus is a TCRa
variable gene locus, the unrearranged humanized TCR variable gene locus comprises at
least one human Voc segment and at least one human Jon segment. in one embodiment
wherein the TCR variable gene locus is a TCRfi variable gene locus, the unrearranged
humanized TCR variable gene locus comprises at least one human Vl3 segment, at least
one human DB segment, and at least one human JB segment. ln various aspects, the
unrearranged humanized TCR variable gene locus is operably linked to the corresponding
endogenous non-human TCR constant region.
A humanized TCR protein made by a non-human animal (e.g., rodent, e.g.,
mouse or rat) as described herein is also provided, wherein the zed TCR n
comprises a human variable region and a non—human constant region. Thus, the humanized
TCR protein ses human complementary determining regions (i.e., human CDR1, 2,
and 3) in its variable domain and a non—human constant region.
Although the Examples that follow describe a genetically engineered non—human
animal whose genome comprises humanized TCRa and/or humanized TCRB variable gene
locus, one skilled in the art would understand that a similar strategy may be used to produce
genetically engineered animals whose genome comprises zed TCRB and/or TCRy
variable gene locus. A genetically engineered non—human animal with humanization of all
four TCR le gene loci is also provided.
Use of Genetically Modified TCR Animals
In various embodiments, the cally modified non—human animals of the
invention make T cells with humanized TCR molecules on their surface, and as a result,
would recognize peptides presented to them by MHC complexes in a human-like manner.
The genetically modified non—human animals described herein may be used to study the
development and function of human T cells and the ses of immunological tolerance;
to test human vaccine ates; to generate TCRs with certain specificities for TCR gene
therapy; to generate TCR libraries to e associated antigens (e.g., tumor associated
antigens (TAAs); etc.
There is a growing st in T cell therapy in the art, as T cells (e.g., xic T
cells) can be directed to attack and lead to destruction of antigen of interest, e.g., viral
antigen, bacterial antigen, tumor antigen, etc, or cells that present it. Initial studies in
cancer T cell therapy aimed at isolation of tumor infiltrating lymphocytes (TlLs; lymphocyte
populations in the tumor mass that presumably comprise T cells reactive against tumor
antigens) from tumor cell mass, expanding them in vitro using T cell growth factors, and
transferring them back to the patient in a process called adoptive T cell transfer. See, e.g.,
Restifo et al. (2012) ve immunotherapy for cancer: harnessing the T cell response,
Nature Reviews 122269-81; Linnermann et al. (2011) T-Cell Receptor Gene Therapy: Critical
Parameters for Clinical Success, J. Invest. Dermatol. 131:1806—16. However, success of
these therapies have thus far been limited to melanoma and renal cell carcinoma; and the
TlL adoptive transfer is not specifically directed to defined tumor associated antigens
. Linnermann et al., supra.
Attempts have been made to initiate TCR gene therapy where T cells are either
selected or programmed to target an n of interest, e.g., a TAA. t TCR gene
therapy relies on identification of sequences of TCRs that are ed to specific antigens,
e.g., tumor ated ns. For example, Rosenberg and colleagues have published
several studies in which they uced peripheral blood lymphocytes derived from a
melanoma patient with genes encoding TCR and chains specific for melanomaassociated
antigen MART-1 epitopes, and used resulting expanded lymphocytes for
adoptive T cell therapy. Johnson et al. (2009) Gene therapy with human and mouse T-cell
ors mediates cancer regression and targets normal s expressing cognate
antigen, Blood 114:535-46; Morgan et al. (2006) Cancer Regression in Patients After
Transfer of Genetically Engineered Lymphocytes, Science 314:126-29. The MART-1
specific TCRs were isolated from patients that experienced tumor sion following TIL
therapy. However, identification of such TCRs, particularly high-avidity TCRs (which are
most likely to be therapeutically useful), is complicated by the fact that most tumor antigens
are self antigens, and TCRs ing these antigens are often either deleted or s
suboptimal affinity, due primarily to immunological tolerance.
In various embodiments, the present invention addresses this problem by
providing genetically ered non-human animals comprising in their genome an
unrearranged human TCR variable gene locus. The non-human animal described herein is
capable of generating T cells with a diverse repertoire of humanized T cell receptors. Thus,
the non-human s bed herein may be a source of a diverse repertoire of
humanized T cell receptors, e.g., high-avidity humanized T cell receptors for use in adoptive
T cell transfer.
Thus, in one embodiment, the present invention provides a method of generating
a T cell receptor to a human antigen comprising immunizing a man animal (e.g., a
rodent, e.g., a mouse or a rat) bed herein with an antigen of interest, allowing the
animal to mount an immune response, isolating from the animal an activated T cell with
specificity for the antigen of interest, and determining the nucleic acid sequence of the T cell
receptor expressed by the antigen-specific T cell.
In one ment, the invention provides a method of producing a human T cell
receptor specific for an antigen of interest (e.g., a disease-associated antigen) comprising
immunizing a non-human animal described herein with the antigen of interest; allowing the
animal to mount an immune response; isolating from the animal a T cell ve to the
n of interest; determining a nucleic acid sequence of a human TCR variable region
expressed by the T cell; g the human TCR variable region into a nucleotide uct
comprising a nucleic acid sequence of a human TCR constant region such that the human
TCR variable region is operably linked to the human TCR nt region; and expressing
from the uct a human T cell receptor specific for the antigen of interest. In one
embodiment, the steps of isolating a T cell, determining a nucleic acid sequence of a human
TCR variable region expressed by the T cell, cloning the human TCR variable region into a
nucleotide uct comprising a nucleic acid sequence of a human TCR constant region,
and expressing a human T cell receptor are performed using standard techniques known to
those of skill the art.
In one embodiment, the nucleotide sequence ng a T cell receptor specific
for an antigen of interest is expressed in a cell. In one embodiment, the cell expressing the
TCR is selected from a CHO, COS, 293, HeLa, PERC.6TM cell, etc.
The antigen of interest may be any antigen that is known to cause or be
associated with a disease or condition, e.g., a tumor associated antigen; an n of viral,
bacterial or other pathogenic origin; etc. Many tumor associated antigens are known in the
art. A selection of tumor associated ns is presented in Cancer Immunity (A Journal of
the Cancer Research Institute) Peptide se
(archive.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm). In some embodiments of
the invention, the n of interest is a human antigen, e.g., a human tumor associated
antigen. In some embodiments, the n is a cell type-specific intracellular antigen, and a
T cell receptor is used to kill a cell expressing the antigen.
In one embodiment, provided herein is a method of identifying a T cell with
specificity against an antigen of interest, e.g., a tumor associated antigen, sing
immunizing a man animal described herein with the antigen of interest, allowing the
animal to mount an immune response, and isolating from the non-human animal a T cell with
icity for the n.
The t invention provides new methods for adoptive T cell therapy. Thus,
provided herein is a method of treating or ameliorating a disease or condition (e.g., a cancer)
in a subject (e.g., a mammalian subject, e.g., a human subject) comprising immunizing a
non—human animal described herein with an antigen ated with the disease or
condition, allowing the animal to mount an immune response, isolating from the animal a
population of antigen-specific T cells, and infusing isolated n-specific T cells into the
t. ln one embodiment, the invention provides a method of treating or ameliorating a
disease or condition in a human subject, comprising immunizing the non—human animal
described herein with an antigen of interest (e.g., a disease- or condition-associated antigen,
e.g., a tumor associated antigen), allowing the animal to mount an immune response,
isolating from the animal a population of antigen—specific T cells, determining the nucleic
acid ce of a T cell receptor expressed by the antigen-specific T cells, g the
nucleic acid sequence of the T cell receptor into an expression vector (e.g., a retroviral
vector), introducing the vector into T cells derived from the subject such that the T cells
express the antigen-specific T cell receptor, and infusing the T cells into the subject. In one
embodiment, the T cell receptor nucleic acid sequence is further humanized prior to
introduction into T cells derived from the subject, e.g., the sequence encoding the non-
human nt region is modified to further resemble a human TCR constant region (e.g.,
the non-human constant region is replaced with a human constant ). in some
embodiments, the disease or condition is cancer. in some embodiments, an antigen-specific
T cell population is expanded prior to ng into the subject. ln some embodiments, the
subject’s immune cell population is immunodepleted prior to the infusion. of antigen-specific
T cells. In some embodiments, the antigen—specific TCR is a high avidity TCR, e.g., a high
avidity TCR to a tumor associated n. In some embodiments, the T cell is a xic T
cell. In other embodiments, the disease or condition is caused by a virus or a bacterium.
in another embodiment, a disease or condition is an autoimmune disease. TREG
cells are a subpopulation of T cells that maintain tolerance to self-antigens and prevent
pathological self—reactivity. Thus, also provided herein are methods of treating autoimmune
disease that rely on generation of antigen—specific TREG cells in the non-human animal of the
invention described herein.
Also provided herein is a method of treating or ameliorating a disease or
condition (e.g., a cancer) in a subject comprising ucing the cells affected by the
disease or condition (e.g., cancer cells) from the subject into a non-human animal, allowing
the animal to mount an immune se to the cells, isolating from the animal a population
of T cells reactive to the cells, determining the nucleic acid sequence of a T cell receptor
expressed by the T cells, cloning the T cell or sequence into a vector, introducing the
vector into T cells derived from the subject, and ng the subject’s T cells harboring the T
cell receptor into the subject.
Also provided herein is the use of a non-human animal as described herein to
make nucleic acid sequences encoding human TCR variable domains (e.g., TCR 0t and/or {3
variable s). in one embodiment, a method is provided for making a nucleic acid
sequence encoding a human TCR le domain, comprising immunizing a non-human
animal as described herein with an antigen of interest, ng the man animal to
mount an immune response to the antigen of interest, and obtaining therefrom a nucleic acid
ce encoding a human TCR variable domain that binds the antigen of interest. in one
embodiment, the method further comprises making a nucleic acid sequence ng a
human TCR variable domain that is operably linked to a non-human TCR constant ,
comprising isolating a T cell from a non-human animal described herein and obtaining
rom the nucleic acid sequence encoding TCR variable domain linked to TCR constant
region.
Also provided herein is the use of a non-human animal as described herein to
make a human therapeutic, comprising immunizing the non—human animal with an antigen of
interest (e.g., a tumor associated antigen), allowing the non-human animal to mount an
immune response, obtaining from the animal T cells reactive to the antigen of interest,
obtaining from the T cells a nucleic acid sequence(s) encoding a humanized TCR protein
that binds the n of interest, and employing the nucleic acid sequence(s) encoding a
humanized TCR protein in a human therapeutic.
Thus, also provided is a method for making a human therapeutic, comprising
immunizing a non—human animal as described herein with an antigen of interest, allowing the
non-human animal to mount an immune response, ing from the animal T cells ve
to the antigen of interest, obtaining from the T cells a nucleic acid sequence(s) encoding a
humanized T cell receptor that binds the antigen of interest, and employing the humanized T
cell receptor in a human therapeutic.
In one embodiment, the human therapeutic is a T cell (e.g., a human T cell, e.g.,
a T cell derived from a human subject) harboring a nucleic acid ce of interest (e.g.,
ected or transduced or otherwise introduced with the nucleic acid of interest) such that
the T cell expresses the humanized TCR protein with ty for an antigen of interest. In
one aspect, a t in whom the therapeutic is ed is in need of therapy for a
particular disease or ion, and the antigen is associated with the disease or ion.
In one aspect, the T cell is a cytotoxic T cell, the antigen is a tumor associated antigen, and
the disease or condition is cancer. In one aspect, the T cell is derived from the subject.
In another embodiment, the human therapeutic is a T cell receptor. In one
ment, the therapeutic receptor is a soluble T cell receptor. Much effort has been
expanded to generate soluble T cell receptors or TCR le regions for use therapeutic
agents. Generation of soluble T cell receptors depends on obtaining rearranged TCR
variable regions. One approach is to design single chain TCRs comprising TCRoc and
TCRB, and, similarly to scFv immunoglobulin format, fuse them together via a linker (see,
e.g., International Application No. ). The resulting sch, if analogous to
scFv, would provide a thermally stable and soluble form of TCRa/B binding protein.
Alternative approaches included designing a soluble TCR having TCRfi constant domains
(see, 6.9., Chung et al., (1994) onal domain single-chain T-ceII receptors, Proc.
Natl. Acad. Sci. USA. 91 :12654-58); as well as engineering a non—native disuifide bond into
the ace between TCR constant domains (reviewed in Boulter and Jakobsen (2005)
Stable, soluble, high-affinity, engineered T cell receptors: novel dy-like proteins for
specific targeting of peptide antigens, CIinical and Experimental Immunoiogy 142:454—60;
see also, US. Patent No. 7,569,664). Other formats of soluble T cell receptors have been
described. The non-human animals described herein may be used to ine a ce
of a T cell or that binds with high affinity to an antigen of interest, and uently
design a soluble T cell receptor based on the sequence.
] A soluble T cell receptor derived from the TCR receptor sequence expressed by
the non—human animal can be used to block the function of a protein of interest, e.g., a viral,
bacterial, or tumor associated protein. Alternatively, a‘s‘bluble T cell receptor may be fused
to a moiety that can kill an infected or cancer cell, e.g., a cytotoxic les (e.g., a
chemotherapeutic), toxin, radionuclide, prodrug, antibody, etc. A soluble T cell receptor may
also be fused to an immunomodulatory molecule, e.g., a cytokine, chemokine, etc. A
soluble T cell receptor may also be fused to an immune inhibitory molecule, e.g., a molecule
that inhibits a T cell from killing other cells harboring an antigen recognized by the T cell.
Such soluble T cell receptors fused to immune inhibitory molecules can be used, e.g., in
blocking autoimmunity. Various exemplary immune inhibitory molecules that may be fused to
a soluble T cell receptor are reviewed in Ravetch and Lanier (2000) immune inhibitory
Receptors, Science 290284-89, incorporated herein by reference.
The present invention also provides s for studying immunological
response in the context of human TCR, including human TCR rearrangement, T cell
development, T cell activation, immunological tolerance, etc.
Also provided are methods of testing vaccine candidates. in one embodiment,
provided herein is a method of determining whether a vaccine will activate an immunological
response (e.g., T cell proliferation, cytokine e, etc), and lead to tion of effector,
as well as memory T cells (e.g., central and or memory T cells).
The invention will be r illustrated by the ing noniimiting examples.
These Examples are set forth to aid in the understanding of the invention but are not
intended to, and should not be construed to, limit its scope in any way. The Examples do not
include detailed descriptions of conventional methods that would be well known to those of
ordinary skill in the art (molecular cloning techniques, etc.). Unless indicated othen/vise,
parts are parts by weight, molecular weight is average molecular weight, temperature is
indicated in Celsius, and pressure is at or near atmospheric.
Example 1. Generation of Mice with Humanized TCR le Gene Loci
Mice comprising a deletion of nous TCR (a or {3) variable loci and
replacement of nous V and J or V, D, and J segments are made using
2012/062065
VELOClGENE® genetic engineering technology (see, 9.9., US Pat. No. 6,586,251 and
Valenzuela, D.M., et al. (2003) High-throughput engineering of the mouse genome coupled
with esolution expression analysis. Nat. Biotech. 21(6): 652-659), wherein human
sequences derived from BAC ies using bacterial homologous recombination are used
to make large targeting vectors (LTVECs) comprising genomic fragments of human TCR
variable loci flanked by targeting arms to target the LTVECs to endogenous mouse TCR
variable loci in mouse ES cells. LTVECs re linearized and oporated into a mouse ES
cell line according to Valenzuela et al. ES cells are selected for hygromycin or neomycin
resistance, and screened for loss of mouse allele or gain of human allele.
Targeted ES cell clones are introduced into 8-cell stage (or earlier) mouse
embryos by the VELOCIMOUSE® method (Poueymirou, W.T. et al. (2007). F0 generation
mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic
analyses. Nat. Biotech. 25: ). VELOClMlCE® (F0 mice fully derived from the donor
ES cell) bearing humanized TCR loci are identified by screening for loss of endogenous
TCR le allele and gain of human allele using a modification of allele assay (Valenzuela
et al.). F0 pups are genotyped and bred to homozygosity. Mice homozygous for humanized
TCRa and/or TCRB variable loci (e.g., comprising a subset of human TCRoc and/or TCRB
variable segments) are made and phenotyped as described herein.
] All mice were housed and bred in the specific pathogen-free facility at Regeneron
ceuticals. All animal experiments were ed by lACUC and Regeneron
ceuticals.
Example 2: Progressive Humanization of TCRa Variable Locus
1.5 megabases of DNA at mouse TCRa locus ponding to 110 V and 60 J
mouse segments was replaced with 1 megabase of DNA corresponding to 54V and 61 J
segments of human TCRoc using a progressive humanization strategy summarized in Fle.
2 and 3. Junctional nucleic acid sequences of various targeting vectors used for progressive
humanization strategy of TCRoc locus are summarized in Table 2, and included in the
Sequence Listing.
Table 2: Junctional Nucleic Acid Sequences for Various TCRa Locus Targeting
Junctional nucleic acid sequence between the 3’ end of mouse
sequence upstream of the TCRoc variable locus and the 5’ end of
loxP-Ub—Hyg-onP cassette.
Description
Junctional nucleic acid sequence between the 3’ end of loxP-Ub-
Hyg-onP cassette and the 5’ end of human 40-TCRVoc41—
TCRJa1 insertion, including AsiSl site.
Junctional nucleic acid ce between the 3’ end of human
TCRVa40-TCRVoc41—TCRJoc1 insertion and the 5’ end of the
mouse sequence downstream of the human TCRa variable locus,
including Notl site.
Junctional nucleic acid sequence between the 3’ end of mouse
sequence upstream of the TCRa variable locus and the 5’ end of
loxP-Ub—Neo—onP cassette.
Junctional c acid sequence between the 3’ end of onP-Ub—
Neo-loxP cassette and the 5’ end of human TCRch35—TCRVa39
insertion, including AsiSl site.
Junctionai nucleic acid sequence between the 3’ end of mouse
sequence am of the TCRoc variable locus and the 5’ end of
frt—ng-Hyg—frt cassette.
Junctional nucleic acid sequence n the 3’ end of frt—ng—
Hyg-frt te and the 5’ end of human TCRVocZZ—TCRVa34
insertion, including AsiSl site.
Junctional nucleic acid sequence between the 3’ end of mouse
sequence upstream of the TCRa variable locus and the 5’ end of
onP-Ub-Neo—IOXP cassette.
onal nucleic acid ce between the 3’ end of loxP-Ub-
Neo-onP cassette and the 5’ end of human TCRVa13—2-
TCRch21 insertion, including AsiSl site.
Junctional nucleic acid sequence between the 3’ end of mouse
sequence upstream of the TCRa variable locus and the 5’ end of
onP—Ub—Hyg—IOXP cassette.
onal c acid sequence between the 3’ end of loxP—Ub—
Hyg-loxP cassette and the 5’ end of human TCRVaG—TCRVa8-5
insertion, including AsiSl site.
Junctional nucleic acid sequence between the 3’ end of mouse
sequence upstream and the TCRa variable locus to the 5’ end of
loxP-Ub-Neo-onP cassette.
Junctional nucleic acid sequence between the 3’ end of onP-Ub-
Neo-onP cassette and the 5’ end of human TCRVai-t-TCRVa5
insertion, including AsiSl site.
Human TCRa le region segments are numbered as in lMGT database. At least 100
bp at each junction (about 50 bp from each end) are included in the Sequence Listing.
Specifically, as trated in , DNA from mouse BAC clone
RP23-6A14 (Invitrogen) was modified by gous recombination and used as a targeting
vector (MAlD 1539) to replace TCRAJ1-TCRAJ28 region of the endogenous mouse TCRa
locus with a Ub-hygromycin cassette followed by a onP site. DNA from mouse BAC clone
RP23—1 17i19 (lnvitrogen) was modified by homologous recombination and used as a
targeting vector (MAID 1535) to replace ~15kb region surrounding (and including) TCRAV1
of the endogenous mouse TCRoc and 6 locus with a PGK—neomycin cassette followed by a
onP site. ES cells g a double-targeted chromosome (i.e., a single endogenous
mouse TCRoc locus targeted with both targeting vectors) were confirmed by karyotyping and
screening methods (e.g., TAQMANTM) known in the art. Modified ES cells were treated with
CRE recombinase, thereby mediating the deletion of the region between the two onP sites
(i.e., the region ting of the endogenous mouse TCRoc locus from TCRAV1 to TCRAJ1)
and leaving behind only a single onP site, neomycin te and the mouse constant and
enhancer regions. This gy resulted in generation of a deleted mouse TCR alts locus
(MAID 1540).
The first human targeting vector for TCRa had 191,660 bp of human DNA from
the CTD2216p1 and CTD2285mO7 BAC clones (lnvitrogen) that contained the first two
consecutive human TCRocV gene segments (TRAV4O & 41) and 61 TCRaJ (50 functional)
gene ts. This BAC was modified by homologous recombination to contain a Not1
site 403 bp downstream (3’) of the TCRocJ1 gene segment for ligation of a 3’ mouse
homology arm and a 5’ AsiSI site for ligation of a 5’ mouse homology arm. Two different
homology arms were used for ligation to this human fragment: the 3’ homology arm
contained endogenous mouse TCRa sequences from the RP23-6A14 BAC clone and the 5’
homology arm contained endogenous TCRa ce 5’ of mouse TCchV from mouse
BAC clone RP23-117i19. This mouse-human chimeric BAC was used as a targeting vector
(MAID 1626) for making an initial insertion of human TCRoc gene segments plus an
upstream onp-ub—hygromycin-loxp cassette at the mouse TCRoc loci (). The
junctional c acid sequences (SEQ ID NOs: 1-3) for the MAID 1626 targeting vector are
described in Table 2.
Subsequently, a series of human targeting vectors were made that utilized the
same mouse 5’ arm that contained endogenous TCRa sequence 5’ of mouse TCRaV from
mouse BAC clone RP23-117i19 with ating onP-neomycin-onP and loxP-hygromycin-
loxP (or gromycin—f/t for MAID 1979) ion tes.
To generate a human TCRa mini—locus containing a total 8 human
TCRaV (7 functional) and 61 human TCRdJ (50 functional) gene segments, DNA from
human BAC clone RP11-349p11 (lnvitrogen) was modified by homologous recombination
and used as a targeting vector (MAID 1767) (). This added 104,846 bp of human
DNA containing the next 6 (5 functional) utive human TCRaV gene segments
(TRAV35 to TRAV39) and a 5’ loxP—ub-neomycin—loxP cassette. Resulting TCRq locus
contained a 5’ loxp-ub-neomycin-JOXP cassette plus a total of 8 human TCRqV (7 functional)
and 61 human TCRaJ gene segments operabiy linked to mouse TCRq nt genes and
enhancers. The junctional nucleic acid ces (SEQ ID NOs: 4 and 5) for the MAID
1767 targeting vector are described in Table 2.
] To generate a human TCRq mini-locus ning total of 23 human TCRocV (17
onal) and 61 human TCRqJ gene segments, DNA from mouse BAC clone ning
from 5’ to 3’: a unique I—Ceul site, a 20 kb mouse TCRA arm 5’ of the mouse TCRA locus to
be used for homologous recombination into ES cells, and a onP—Ub—Hyg~/oxP te in
reverse orientation, was modified by bacterial homologous recombination to contain from 5’
to 3’: a unique I—Ceul site, a 20 kb mouse TCRA arm 5’ of the mouse TCRA locus, an frt—
pgk-Hyg-frt cassette, and a unique AsiSI site. DNA from human BAC clone RP11-622020
(Invitrogen), harboring human TCRaV22-V34 was modified by homoiogous recombination to
contain a Spec te flanked by unique I-CeuI and AsiSI sites. Subsequently, the Spec
cassette in the ed human BAC clone was replaced by the sequence comprised
between the l-CeuI and AsiSI sites in the modified mouse BAC clone by standard restriction
digestion/ligation techniques. The resulting targeting vector (MAID 1979; ) added
136,557 bp of human DNA that contained the next 15 (1O functional) consecutive human
TCRqJ gene ts (TRAV22 to TRAV34) and a 5’ frt—pgk—Hyg-fn‘ cassette. Resuiting
TCch locus contained a 5’ frt-pgk-Hyg-frt cassette plus a total of 23 human TCRocV (17
functional) and 61 human TCRocV gene segments operably linked to mouse TCRoc constant
genes and enhancers. The onaI nucIeic acid sequences (SEQ ID NOs: 6 and 7) for the
MAID 1979 targeting vector are described in Tabie 2.
To generate human TCRa mini-locus containing a totaI of 35 human TCRaV (28
functional) and 61 human TCRaJ gene segments, DNA from human BAC cIone CTD2501—
k5 (Invitrogen) was modified by homologous recombination and used as a targeting vector
(MAID 1769) (). This added 124,118 bp of human DNA that contained the next 12
(11 functionaI) consecutive human TCRqV gene segments (TRAV13-2 to ) and a 5’
loxp-ub-neomycin-loxP cassette. Resulting TCRa locus contained a 5’ loxp-ub—neomycin-
loxP cassette plus a total of 35 human TCRocV (28 functional) and 61 human TCRqJ gene
segments operably linked to mouse TCRoc constant genes and enhancers. The junctional
nucIeic acid sequences (SEQ ID NOs: 8 and 9) for the MAID 1769 targeting vector are
described in Table 2.
WO 63361
To generate a human TCRa mini-locus containing total of 48 human TCRaV (39
functional) and 61 human TCRaJ gene segments, DNA from human BAC clone RP11-
92F11 (lnvitrogen) was modified by homologous recombination and used as a targeting
vector (MAlD 1770) (HS. 4F). This added 145,505 bp of human DNA that contained the
next 13 (11 functional) consecutive human TCRaJ gene segments (TRAV6 to TRAV8.5) and
a 5’ onp-ub—hygromycin-loxP cassette. ing TCRa locus contains a 5’ loxp—ub—
hygromycin-onP cassette plus a total of 48 human TCRaV (39 functional) and 61 human
TCRaJ gene segments operably linked to mouse TCRa constant genes and enhancers.
Thejunctional nucleic acid ces (SEQ ID N05: 10 and 11) for the MAID 1770
targeting vector are described in Table 2.
To generate a human TCRa mini-locus containing total of 54 human TCRorV (45
functional) and 61 human TCRaJ gene segments, DNA from human BAC clone RP11-
780M2 (lnvitrogen) was modified by homologous ination and used as a ing
vector (MAlD 1771) (). This added 148,496 bp of human DNA that contained the
next 6 (6 functional) consecutive human TCRaV gene ts (TRAV1—1 to TRAV5) and a
’ onp-ub—neomycin-onP cassette. Resulting TCRa locus contains a 5’ onp-ub—neomycin-
onP cassette plus a total of 54 human TCRaV (45 functional) and 61 human TCRaJ gene
segment operably linked to mouse TCRa constant genes and enhancers. The junctional
nucleic acid sequences (SEQ ID N05: 12 and 13) for the MAlD 1771 targeting vector are
described in Table 2.
In any of the above steps, the selection cassettes are removed by deletion with
Cre or Flp recombinase. In addition, human TCRa locus may be introduced as depicted in
Example 3: Progressive Humanization of TCRfi Variable Locus
0.6 megabases of DNA at mouse TCRfS locus corresponding to 33 V, 2 D, and 14
J mouse ts were ed with 0.6 megabases of DNA corresponding to 67 V, ZD,
and 14 J segments of human TCRfi using a progressive humanization strategy summarized
in Fle 6 and 7. Junctional nucleic acid sequences of various targeting s used for
progressive humanization strategy of TCRB locus are summarized in Table 3, and included
in the Sequence Listing.
Table 3: Junctional Nucleic Acid Sequences for s TCRB Locus Targeting
Vectors
MAID SEQ lD Description
NO. NO
14 Junctional nucleic acid sequence between the 3’ end of mouse
sequence upstream of the TCRB le locus y the
am mouse trypsinogen genes) and the 5’ end of frt-Ub-Neo—
fn‘ cassette.
Junctional nucleic acid sequence between the 3’ end of frt-Ub-
Neo-frt cassette and the 5’ end of human TCRVBtB—TCRVBZQ-t
insertion.
Junctional c acid sequence between the 3’ end of human
TCRVB18-TCRV529-1 insertion and the 5’ end of the mouse
sequence downstream of the mouse TCRVlS segments (nearby
downstream mouse trypsinogen genes).
Junctional nucleic acid sequence between 3’ of the downstream
mouse trypsinogen genes and the 5’ end of human TCRD(31—
TCRJB1TCRJBt—6 ion, ing lceul site.
onal nucleic acid sequence between the 3’ end of human
TCRDBt-TCRJB1TCRJBt-6 insertion and the 5’ end of loxP—
Ub—Hyg-loxP cassette.
Junctional nucleic acid sequence between the 3’ end of -
Hyg-loxP cassette and the 5’ end of mouse ce nearby the
mouse CB1 gene.
Junctional nucleic acid sequence between the 3’ end of the
mouse sequence nearby the mouse C(31 gene and the 5’ end of
human TCRDBZ—TCRJBZ-t—TCRJBZJ insertion, including Notl
site.
21 Junctional nucleic acid sequence between the 3’ end of human
TCRDfiZ-TCRJBZTCRJBZ-7 insertion and the 5’ end of the
mouse sequence downstream of the TCRfi‘» variable locus y
the 032 mouse sequence).
22 Junctional nucleic acid sequence between the 3’ end of mouse
sequence upstream of the TCRB variable locus (nearby the
upstream mouse trypsinogen genes) and the 5’ end of frt-Ub-Hyg-
1791 frt cassette.
3 Junctional nucleic acid sequence between the 3’ end of frt-Ub—
Hyg-frt cassette and the 5’ end of human TCRVfiB—5-TCRV517
insertion.
24 Junctional nucleic acid sequence between the 3’ end of mouse
sequence upstream of the TCRfs variable locus (nearby the
upstream mouse nogen genes) and the 5’ end of frt-Ub-Neo-
1792
frt cassette.
Junctional nucleic acid sequence between the 3’ end of frt-Ub-
H o-frt cassette and the 5’ end of human TCRV 1—TCRV 12—2
SEQ ID Description
NO. NO
insertion.
Junctional nucleic acid sequence between the 3’ end of mouse
sequence nearby the mouse CB2 gene and the 5’ end of the
human TCRBV30 exon 2 sequence.
6192
Junctional nucleic acid sequence between the 3’ end human
TCRBV30 exon 1 sequence and the 5’ end of mouse sequence
downstream of TCR|3 locus.
Human TCRB variable region ts are numbered as in lMGT database. At least 100
bp at each junction (about 50 bp from each end) are included in the Sequence Listing.
Specifically, DNA from mouse BAC clone RP23—153p19 (lnvitrogen) was
modified by homologous recombination and used as a targeting vector (MAlD 1544) to
replace 17kb region (including TCRBV30) just upstream of the 3’ trypsinogen gene cluster in
the endogenous mouse TCRB locus with a PGK-neo cassette followed by a onP site
(FlG. 8A). DNA from mouse BAC clone RP23—461h15 (lnvitrogen) was modified by
gous recombination and used as a targeting vector (MAlD 1542) to replace 8355 bp
region (including TCRBV2 and TCRBV3) downstream of 5’ trypsinogen gene cluster in the
endogenous mouse TCRB locus with a Ub-hygromycin cassette ed by a onP site. ES
cells bearing a double~targeted chromosome (Le, a single endogenous mouse TCRB locus
targeted with both targeting vectors) were confirmed by karyotyping and screening methods
(9.9., TAQMANTM) known in the art. Modified ES cells were treated with CRE recombinase,
mediating the on of the region n the 5’ and 3’ loxP sites (consisting of the
endogenous mouse TCRB locus from TCRBV2 to 0) and leaving behind only a
single onP site, hygromycin cassette and the mouse TCRBDs, TCRBJs, constant, and
enhancer sequences. One mouse TCRVfi was left am of the 5’ cluster of nogen
genes, and one mouse TCRBfS was left downstream of the mouse Eff», as noted in Fig 8A.
The first human targeting vector for TCRB had 125,781 bp of human DNA from
the CTD2559j2 BAC clone (lnvitrogen) that ned the first 14 consecutive human
TCRfiV gene segments (TRBV18—TRBV29—1). This BAC was modified by gous
recombination to contain a 5’ AsiSl site and a 3’ Ascl site for ligation of a 5’ and 3’ mouse
homology arms. Two different homology arms were used for on to this human
fragment: one set of homology arms contained endogenous TCRf3 sequence surrounding
the downstream mouse trypsinogen genes from the RP23—1 53p19 BAC clone and another
set ned endogenous TCRfi ce surrounding the upstream mouse trypsinogen
genes from mouse BAC clone RP23-461h15. This mouse-human chimeric BAC was used
as a targeting vector (MAID 1625) for making an initial insertion of human TCRfi gene
ts plus an upstream frt-ub-neomycin-frt te at the mouse TCRp locus, and
resulted in a human TCRB mini-locus containing 14 human (8 functional) TCRBV (FIG. BB).
Thejunctional nucleic acid sequences (SEQ ID NOs: 14-16) for the MAID 1625 targeting
vector are described in Table 3.
In order to replace mouse TCRfi D and J segments with human TCRB D and J
segments, DNA from mouse BAC clone RP23—302p18 (lnvitrogen) and from human BAC
clone RP11-701D14 (lnvitrogen) was modified by homologous recombination and used as a
targeting vector (MAID 1715) into the ES cells that contained the TCRBV mini-locus
described above (i.e., MAID 1625). This modification replaced ~18540 bp region (from 100
bp downstream of the polyA of the 3’ trypsinogen genes to 100bp downstream from the J
segments in the D2 cluster which included mouse TCRBD1-J1, mouse constant 1, and
mouse TCRBD2-J2) in the endogenous mouse TCRB locus with ~25425 bp of sequence
containing human TCRBD1-J1, loxP Ub-hygromycin-onP cassette, mouse constant 1,
human TCRBD2—J2 ((i)). ES cells bearing a double-targeted chromosome (Le, a
single endogenous mouse TCRfi locus targeted with both ing vectors) were confirmed
by karyotyping and screening methods (e.g., TAQMANTM) known in the art. Modified ES
cells were d with CRE recombinase thereby mediating the on the hygromycin
cassette leaving behind only a single onP site downstream from human J segments in D1J
cluster ((ii)). Thejunctional nucleic acid sequences (SEQ ID NOs: 17-21) for the
MAID 1715 targeting vector are described in Table 3.
] Subsequently, a series of human targeting vectors were made that utilized the
same mouse 5’ arm that contained endogenous TCRB sequence surrounding the upstream
mouse trypsinogen genes from mouse BAC clone RP23-461h15 with alternating selection
cassette.
] To generate a human TCRB mini-locus containing a total 40 human
TCRfiV (30 functional) and the human TCRB D and J segments, DNA from human BAC
clones RP11—134h14 and RP11-785k24 (lnvitrogen) was modified by homologous
recombination and combined into a targeting vector (MAID 1791) using standard bacterial
gous recombination, restriction digestion/ligation, and other cloning techniques.
Introduction of the MAID 1791 targeting vector ed in addition of 198,172 bp of human
DNA that ned the next 26 (22 onal) consecutive human TCRBV gene segments
(TRBV6—5 to TRBV17) and a 5’ frt—ub—hygromycin-frt cassette. Resulting TCRp locus
contained a 5’ frt—ub-hygromycin—frt cassette plus a total of 40 human TCR|3V (30 onal)
and human TCRB D and J gene segments ly linked to mouse TCRB constant genes
and enhancers (). The junctional nucleic acid sequences (SEQ ID NOs: 22 and 23)
for the MAID 1791 targeting vector are described in Table 3.
To generate a human TCRB mini—locus containing a total 66 human
TCRBV (47 functional) and the human TCRB D and J segments, DNA from human BAC
clone RP11-902B7 (lnvitrogen) was modified by homologous recombination and used as a
targeting vector (MAID 1792). This resulted in addition of 2 bp of human DNA that
contained the next 26 (17 functional) consecutive human TCRBV gene segments (TRBV1 to
TRBV12-2) and a 5’ —neomycin—fn‘ cassette. Resulting TCRB locus contained a 5’ fri—
ub—neomycin-fn‘ cassette plus a total of 66 human TCRBV (47 onal) and human
TCRB D and J gene segments ly linked to mouse TCRB constant genes and
enhancers. (). The junctional nucleic acid sequences (SEQ ID N05: 24 and 25) for
the MAID 1792 targeting vector are described in Table 3.
In any of the above steps, the selection cassettes are removed by deletion with
Cre or Flp recombinase. For example, as depicted in MAID 1716 corresponds to
MAID 1715 with the hygromycin cassette deletion.
Finally, a human TCRB mini-locus containing a total 67 human
TCRBV (48 functional) and the human TCRfi D and J segments was generated. Mouse
TCRBV31 is located ~94 kb 3’ of TCRBCZ (second TCRB constant region ce) and is
in the opposite orientation to the other TCRBV ts. The equivalent human V segment
is TCRBV30, which is located in a similar position in the human TCRB locus.
To humanize TCRBV31, the mouse BAC clone containing mouse TCRBV31, was
modified by bacterial homologous recombination to make LTVEC MAID 6192 (). The
entire coding , beginning at the start codon in exon 1, the intron, the 3’ UTR, and the
recombination signal sequences (RSS) of TCRBV31 were replaced with the homologous
human TCRBV30 sequences. The 5’ UTR was kept as mouse sequence. For selection, a
self-deleting cassette (lox2372-Ubiquitin promoter-Hyg-PGKpolyA—Protamine promoter-Cre-
SV40polyA-on2372) was inserted in the intron (72 bp 3’ of exon 1,289 bp 5’ of exon 2). For
city, FIGS. 7 and 8 depict the selection cassette 3’ of the hTCRBV30, while it was
engineered to be located in the intron n exon 1 and exon 2 of the 3O gene.
The protamine promoter g Cre expression is transcribed ively in post—meiotic
spermatids, so the cassette is “self-deleted” in the F1 generation of mice.
The junctional nucleic acid sequences (SEQ ID N03: 26 and 27) for the MAID
6192 targeting vector are described in Table 3. MAID 6192 DNA is electroporated into
MAID1792 ES cells. ES cell clones are selected for hygromycin-resistance and screened for
loss of mouse TCRB31 allele and gain of human TCRB30 allele.
Similar engineering strategy is used to optionally delete the remaining 5’ mouse
TCRB V segment.
Example 4: Generation of TCRa/TCRfi Mice
At each step of progressive humanization of TCRa and TCRfi loci, mice
homozygous for humanized TCRa variable locus may be bred with mice homozygous for
humanized TCRB variable locus to form progeny sing humanized TCRa and TCRB
variable loci. Progeny are bred to homozygosity with respect to humanized TCRa and
humanized TCRfi loci.
In one embodiment, mice gous for humanized TCRoc variable locus
sing 8 human Von and 61 human Jet (MAID 1767; “1767 H0”) were bred with mice
homozygous for humanized TCRB variable locus comprising 14 human VB, 2 human DB,
and 14 human J8 (MAID 1716; “1716 H0”). Progeny were bred to homozygosity with
respect to both humanized loci.
Example 5: Splenic T cell tion in Mice gous for zed TCRot
and/or TCRfl Locus
Spleens from wild type (WT) mice; mice with d mouse TCRa locus
(“MAID1540”, see ; mice gous for human TCRa locus (“MAID 1767”, see
; mice with deleted TCRfi V segments with the exception of two remaining mouse V
segments (“MAID1545”, see ; mice homozygous for human TCR{3 locus, also
comprising the two remaining mouse V segments (“MAID 1716”, see ; and mice
homozygous for both human TCRoc and TCRB loci, with TCRB locus also comprising the two
remaining mouse V segments (“MAID 1767 1716”) were perfused with Collagenase D
(Roche Bioscience) and erythrocytes were lysed with ACK lysis buffer, followed by washing
in RPMI medium.
Splenocytes from a single WT, MAID 1540, 1767, 1545, 1716, and 1716 1767
representative animal were evaluated by flow try. Briefly, cell suspensions were
made using standard methods. 1x106 cells were ted with anti—mouse CD16/CD32
(2.4G2, BD) on ice for 10 minutes stained with the appropriate cocktail of antibodies for 30
minutes on ice. Following staining, cells were washed and then fixed in 2% formaldehyde.
Data acquisition was performed on an LSRll/Cantoll/LSRFortessa flow ter and
analyzed with FlowJo.
WO 63361
For staining of splenocytes, anti—mouse FlTC-CD3 (17A2, BD) was used. As
demonstrated in mice with human TCR segments were able to produce significant
numbers of CD3+ T cells, while mice with TCRd mouse locus deletion did not. Mice with
TCRB locus deletion also produced CD3+ T cells, presumably due to utilization of the
ing 3’ mouse V segment (see below).
Example 6: Thymic T Cell Development in Mice Homozygous for Humanized TCRa
and/or TCRfi Locus
To determine whether mice homozygous for humanized TCRoc and/or TCRB
locus exhibited normal T cell development in the thymus, cytes from four of each WT,
1767 H0, 1716 H0, and 1716 H0 1767 H0 age matched animals (7-10 weeks old) were
used in flow cytometry to te production of T cells at various developmental stages, as
well as to evaluate frequency and absolute number of each of DN, DP, CD4 SP, and CD8
SP T cells.
Cell type determinations were made based on the presence of CD4, CD8, CD44,
and CD25 cell surface markers as summarized in Table 1. Correlation n cell type
designation and expression of cell surface markers in the thymus is as follows: double
negative (DN) cells (CD4— CD8-), double positive (DP) cells (CD4+ CD8+), CD4 single
positive cells (CD4+ CDS-), CD8 singie positive cells (CD4— CD8+), double ve 1/DN1
cells (CD4- CD8-, CD25- CD44+), double negative 2/DN2 cells (CD4- CD8—, CD25+
CD44+), double negative 3/DN3 cells (CD4- CD8—, CD25+ CD44-), double negative 4/DN4
cells (CD4- CD8-, CD25- CD44-).
Thymocytes were evaluated by flow cytometry. Briefly, cell suspensions were
made using standard methods. Flow cytometry was conducted as described in Example 5.
Antibodies used were: anti—mouse PE-CD44 (lM7, BioLegend), PeCy7-CD25 (PC61,
BioLegend), APC-H7-CD8a (53-67, BD), and APC-CD4 (GK1.5, eBioscience).
As shown in Fle 10 and 11, mice homozygous for humanized TCRoc, TCRB,
and both TCRa and TCRp were able to produce a DN1, DN2, DN3, DN4, DP, CD4 SP, and
CDS SP T cells, indicating that the T cells produced from the humanized loci are capable of
undergoing T cell development in the thymus.
Example 7: c T Cell entiation in Mice Homozygous for Humanized TCRa
and/or TCRB Locus
] To determine whether mice homozygous for humanized TCRa and/or TCRfi
locus exhibited normal T cell differentiation in the periphery (e.g., ), four of each WT,
1767 H0, 1716 H0, and 1716 H0 1767 H0 age matched animals (7-10 weeks old) were
WO 63361
used in flow cytometry to evaluate production of various T cell types in the spleen (CD3+,
CD4+, CD8+, T naive, Tom, and Teff/em), as well as to evaluate the absolute number of
each T cell type in the spleen.
Cell type determinations were made based on the presence of CD19 (8 cell
marker), CD3 (T cell marker), CD4, CD8, CD44, and CD62L (L-selectin) cell surface
markers. Correlation between cell type designation and expression of cell surface s
in the spleen is as follows: T cells (CD3+), CD4 T cells (CD3+ CD4+ CD8—), CD8 T cells
(CD3+ CD4- CD8+), CD4 effector/effector memory T cells (CD3+ CD4+ CD8— CD62L-
, CD4 central memory T cells (CD3+ CD4+ CD8- CD62L+ CD44+), CD4 naive T
cells (CD3+ CD4+ CD8- CD62L+ CD44-), CD8 effector/effector memory T cells (CD3+ CD4-
CD8+ CD62L- CD44+), CD8 central memory T cells (CD3+ CD4— CD8+ CD62L+ ,
CD8 naive T cells (CD3+ CD4- CD8+ CD62L+ CD44-).
Splenocytes were evaluated by flow cytometry. y, cell sions were
made using standard methods. Flow cytometry was conducted as described in Example 5.
Antibodies used were: ouse FITC-CD3 (17A2, BD), PE-CD44 (IM7, BioLegend),
Cy5.5—CD62L (Mel-14, end), APC-H7-CD8a (53-67, BD), APC—CD4 (GK1.5,
ience), and V450-CD19 (1 D3, BD).
As shown in FIGS. 12-14, T cells in the spleen of mice homozygous for
humanized TCRd, TCRB, and both TCRoc and TCRB were able to undergo T cell
differentiation, and both CD4+ and CD8+ T cells were present. In addition, memory T cells
were detected in the spleens of the mice tested.
Example 8: Utilization of Human V Segments in Humanized TCR Mice
Expression of human TCR[3 V segments was evaluated on protein and RNA level
using flow cytometry and TAQMANTM real-time PCR, respectively, in mice homozygous for
humanized TCRB locus (1716 H0) and mice homozygous for both humanized TCRB and
TCRa locus (1716 H0 1767 H0).
For flow cytometry, c T cell were prepared and analysis conducted as
described in Example 5. For flow cytometry, TCRB repertoire kit (lOTEST® Beta Mark,
Beckman Coulter) was used. The kit contains anti-human antibodies specific for a number
of human TCRBVs, e.g., hTRBV—18, -19, -20, -25, -27, -28, and —29.
Results are summarized in . The tables presented in A (CD8 T
cell overlay) and B (CD4 T cell y) demonstrate that splenic T cells in both 1716
H0 and 1716 H0 1767 H0 mice utilized a number of human TCRB V segments. The wild
type mice were used as a negative control.
] For real—time PCR, total RNA was purified from spleen and thymus using
MAGMAXTM-96 for Microarrays Total RNA Isolation Kit (Ambion by Life Technologies)
according to manufacturer's ications. Genomic DNA was d using
MAGMAXTMTURBOTMDNase Buffer and TURBO DNase from the MAGMAX kit listed above
(Ambion by Life Technologies). mRNA (up to 2.5ug) was reverse—transcribed into cDNA
using SUPERSCRIPT® VILOTM Master Mix (Invitrogen by Life Technologies). cDNA was
diluted to nL, and 10-25ng cDNA was ed with the TAQMAN® Gene Expression
Master Mix (Applied Biosystems by Life Technologies) using the ABI 79OOHT Sequence
Detection System (Applied Biosystems), using the primers and Taqman MGB probes
ed Biosystems) or BHQ1/BHQ-Plus probes (Biosearch Technologies) depicted in
Table 4 according to manufacturer’s instructions. The relative expression of each gene was
normalized to the murine TCR beta constant 1 (TRBCl) l.
Table 4: Primers and Probes Used for Detecting RNA Expression of TCRB V
Segments and Constant Region in Humanized TCR Mice by Real-Time PCR
(TAQMANW)
TRBV Sense Primer (5’-3’) Antisense Primer (5’-3’) Probe (5’-3’)
E-E-E
hTRBV CCGGCGTCATGC 28 GGGCTGCATCTCAGT 29
18 AGAA CTTGC CACCTGGTCAGG
AGGAGG —MGB
hTRBV GGAATCACTCAG ATTCTGTTCACAACTC 32
19 TCCCCAAAG A TCAGAAAGGAAG
GACAGAAT-MGB
hTRBV CGAGCAAGGCGT 34 GGACAAGGTCAGGCT 35 FAM-
CGAGAA TGCA ACAAGTTTCTCAT
CAACC- MGB
TGTTACCCAGAC 37 TCTGAGAACATTCCA FAM-
CCCAAGGA GCATAATCCT TAGGATCACAAAG
ACAGGAA-MGB
GACCCT 4O TGCTGGCACAGAGGT FAM-
GGAGTCT ACTGAGA CAGGCCCTCACAT
AC- MGB
AAGCCCAAGTGA ATTCTGAGAACAAGT FAM—
CCCAGAA CACTGTTAACTTC CTCATCACAGTGA
CTGGAA- MGB
2012/062065
TRBV Sense Primer (5’-3’) Antisense Primer (5’-3’) Probe (5’-3’)
Sequence SED Sequence SED ce 559
ID NO ID NO ID No
hTRBV GTGAAAGTAACC 46 ATCCTGGACACATTC 47 FAM- 48
28 CAGAGCTCGAG CAGAAAAAC ATATCTAGTCAAA
AGGACGGGA-
TGTCATTGACAA TGCTGTCTTCAGGGC FAM- 51
GTTTCCCATCAG TCATG TCAACTCTGACTG
TGAGCA— MGB
AGCCGCCTGAGG GCCACTTGTCCTCCT FAM— 54
1 GTCTCT CTGAAAG TACCTTCTGGCAC
AATCCTCGCA —
As demonstrated in FIGs. 16A—B, mice homozygous for humanized TCRfi locus
(1716 H0) and mice homozygous for both humanized TCRB and TCRa locus (1716 H0
1767 H0) exhibited RNA expression of various human TCRB segments in both the thymus
and the spleen. Mice also exhibited RNA expression of mouse TRBV—1 and TRBV—31
segments (data not shown), but no mouse TRBV-1 protein was detected by flow cytometry
(data not shown).
Mouse TRBV-31 segment is replaced with human TRBV—30 segment as
demonstrated in , and mice are generated from MAID 6192 ES cells as bed
. The spleens and thymi of ing homozygous animals are tested for utilization of
human VB segments, including TRBV-30, by flow cytometry and/or real—time PCR as
described herein. mTRBV—1 segment may also be deleted.
Example 9: T Cell Development in Mice Homozygous for 23 Human TCR Va
Segments
Homozygous humanized TCRoc mice characterized in the previous examples
ned 8 human Va segments and 61 human Joe segments (1767 H0, see .
Homozygous humanized TCRoc mice comprising 23 human Va segments and 61 human Ja
segments (1979 H0, see were tested for their y to te splenic CD3+ T
cells and exhibit T cell development in the thymus.
mental data was obtained using flow cytometry using appropriate
antibodies as described in the preceding es. As depicted in , a mouse
homozygous for 23 human Von segments and 61 human Jo: segments produced a significant
number of splenic CD3+ T cells, and the percent of eral CD3+ T cells was comparable
to that of the wild type animals ().
Moreover, thymocytes in 1979 H0 mice were able to undergo T cell development
and contained T cells at DN1, DN2, DN3, DN4, DP, CD4 SP, and CD8 SP stages (FlG. 18).
Example 10: T Cell pment and Differentiation in Mice Homozygous for a
te Repertoire of Both Human TCR: and TCR [3 Variable Region Segments
Mice homozygous for a te repertoire of human TCRa variable region
segments (Le, 54 human Von and 61 human Jon) and gous for a complete repertoire
of human TCRB variable region segments (67 human VB, 2 human DB, and 14 human J3),
“1771 H0 6192 H0” (see Fle. 3 and 7), are tested for their ability to produce thymocytes
that undergo normal T cell development, produce T cells that undergo normal T cell
differentiation in the periphery, and utilize the complete repertoire of their human Va and VB
segments.
Flow cytometry is conducted to determine the presence of DN1, DN2, DN3, DN4,
DP, CD4 SP and CD8 SP T cells in the thymus using anti—mouse CD4, CD8, CD25, and
CD44 antibodies as described above in Examples 5 and 6. Flow cytometry is also
conducted to determine the number of CD3+ T cells in the periphery, as well as to evaluate
T cell differentiation in the ery (e.g., presence of effector and memory T cells in the
periphery). The experiment is conducted using anti-mouse CD3, CD19, CD4, CD8, CD44,
and CD62L antibodies as bed above in Examples 5 and 7,
Finally, flow cytometry and/or ime PCR are conducted to determine whether
T cells in 1771 H0 6192 H0 mice utilize a complete repertoire of TCRB and TCRA V
segments. For protein expression using flow cytometry, TCRB repertoire kit (lOTEST® Beta
Mark, Beckman Coulter), containing anti—human hTCRBV—specific antibodies, is utilized (see
Example 8). For RNA expression using ime PCR, cDNAs from spleens or thymi are
amplified using human TCR-V primers and Taqman , according to manufacturers
instructions and as described above in Example 8.
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than
routine experimentation, many lents of the specific embodiments of the invention
described . Such equivalents are intended to be encompassed by the following
claims.
Entire contents of all non-patent documents, patent applications and patents cited
throughout this application are incorporated by reference herein in their entirety.
Where the terms “comprise”, ises”, “comprised” or “comprising” areused
in this specification (including the claims) they are to be reted as specifying the
ce of the stated features, integers, steps or ents, but not precluding the
presence of one or more other features, integers, steps or components, or group thereof.
] The discussion of documents, acts, materials, devices, articles and the like is
included in this specification solely for the purpose of providing a context for the present
invention. It is not suggested or represented that any or all of these matters formed part of
the prior art base or were common general knowledge in the field relevant to the present
invention as it existed before the priority date of each claim of this application.
Claims (21)
1. A genetically modified non-human animal, comprising in its genome: an unrearranged T cell receptor (TCR) variable gene locus comprising at least one human V t and at least one human J segment, wherein the TCR variable gene locus is operably linked to a man TCR nt gene sequence, wherein the unrearranged TCR variable gene locus replaces an endogenous non-human TCR variable gene locus, and/or an unrearranged TCR variable gene locus sing at least one human V segment, at least one human D segment, and at least one human J segment, wherein the unrearranged TCR variable gene locus is operably linked to a non-human TCR constant gene sequence, wherein the unrearranged TCR variable gene locus replaces an endogenous man TCR variable gene locus.
2. The animal of claim 1, wherein endogenous man V and J segments are incapable of rearranging to form a rearranged V/J sequence and/or endogenous rodent V, D, and J segments are incapable of rearranging to form a rearranged V/D/J sequence.
3. The animal of claim 1, wherein the animal lacks a onal endogenous non-human TCR and/or TCR variable locus.
4. The animal of claim 3, wherein the lack of the functional endogenous non-human TCR variable gene locus comprises a on selected from the group consisting of (a) a deletion of all endogenous V gene segments, (b) a deletion of all endogenous J gene segments, and (c) a combination thereof and/or the lack of the functional endogenous rodent TCR variable gene locus comprises a deletion selected from the group ting of (a) a deletion of all endogenous V gene segments, (b) a on of all endogenous D gene segments, (c) a deletion of all endogenous J gene segments, and (d) a combination thereof.
5. The animal of claim 1, wherein the human V and J segments rearrange to form a rearranged human V/J sequence and/or the human V, D, and J segments rearrange to form a rearranged human V/D/J sequence.
6. The animal of any one of claims 1 to 5, wherein the animal expresses a T cell or comprising a human TCR and/or TCR variable region on the surface of a T cell.
7. The animal of any one of claims 1 to 6, wherein T cells of the animal undergo thymic T cell development to produce CD4 and CD8 single positive T cells.
8. The animal of any one of claims 1 to 7, wherein the animal comprises a normal ratio of splenic CD3+ T cells to total splenocytes.
9. The animal of any one of claims 1 to 8, wherein the animal generates a tion of central and effector memory T cells to an antigen of interest.
10. The animal of any one of claims 1 to 9, wherein the unrearranged TCR variable gene locus comprises a complete repertoire of human J segments and a complete repertoire of human V segments and/or the ranged TCR variable gene locus comprises a complete repertoire of human J segments, a complete repertoire of human D segments, and a te repertoire of human V segments.
11. The animal of claim 1, wherein the animal retains an endogenous non-human TCR variable gene locus and/or an endogenous non-human TCR variable gene locus, and n the endogenous non-human TCR variable gene locus and/or the endogenous nonhuman TCR variable gene locus is a non-functional locus.
12. The animal of any one of claims 1 to 11, wherein the animal is a rodent.
13. The animal of claim 12, n the rodent is a mouse.
14. A genetically modified non-human animal according to any one of claims 1 to 13, comprising in its : an unrearranged T cell receptor (TCR) variable gene locus comprising at least one human V t and at least one human J segment, operably linked to a non-human TCR constant gene sequence; and, an unrearranged TCR variable gene locus comprising at least one human V segment, at least one human D segment, and at least one human J segment, operably linked to a non-human TCR constant gene ce.
15. The animal of claim 14, wherein the animal expresses a T cell receptor comprising a human variable region and a non-human constant region on a surface of a T cell.
16. The animal of claim 14, wherein the unrearranged TCR variable gene locus comprises 61 human J segments and 8 human V segments, and n the unrearranged TCR variable gene locus comprises 14 human J segments, 2 human D segments, and 14 human V segments.
17. The animal of claim 14, wherein the animal r comprises an unrearranged TCR variable region locus comprising human V segments.
18. The animal of claim 17, wherein the animal further comprises a complete repertoire of human V segments, a complete repertoire of human D segments, and a complete repertoire of human J segments at the humanized TCR locus.
19. A genetically modified non-human animal according to any one of claims 1 to 18, wherein the non-human animal is a mouse comprising in its genome: an unrearranged T cell receptor (TCR) variable gene locus sing a complete repertoire of human J segments and a te repertoire of human V segments, operably linked to a mouse TCR constant gene sequence, and an unrearranged TCR variable gene locus comprising a complete repertoire of human J segments, a complete repertoire of human D segments, and a complete repertoire of human V segments, operably linked to a mouse TCR constant gene sequence.
20. A method of producing a human T cell receptor to an antigen of interest comprising: immunizing a non-human animal of any one of claims 1 to 19 with the antigen of interest; allowing the animal to mount an immune response; ing from the animal a T cell reactive to the antigen of interest; determining a nucleic acid sequence of a human TCR variable region expressed by the T cell; cloning the nucleic acid sequence of the human TCR variable region into a nucleotide uct comprising a c acid sequence of a human TCR constant region, wherein the nucleic acid sequence of the human TCR variable region is operably linked to the nucleic acid sequence of the human TCR nt region; and expressing a human T cell receptor in a cell.
21. The genetically modified non-human animal of claim 1, substantially as hereinbefore described with reference to the es and/or
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552582P | 2011-10-28 | 2011-10-28 | |
US61/552,582 | 2011-10-28 | ||
US201261621198P | 2012-04-06 | 2012-04-06 | |
US61/621,198 | 2012-04-06 | ||
US201261700908P | 2012-09-14 | 2012-09-14 | |
US61/700,908 | 2012-09-14 | ||
PCT/US2012/062065 WO2013063361A1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified t cell receptor mice |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623147A NZ623147A (en) | 2016-03-31 |
NZ623147B2 true NZ623147B2 (en) | 2016-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021203192B2 (en) | Genetically modified t cell receptor mice | |
NZ623147B2 (en) | Genetically modified t cell receptor mice |